

Clarivate Consulting Services Publication list



Contents

At Clarivate, we have extensive experience publishing manuscripts and conference abstracts across a comprehensive range of therapy and domain areas. Please see below for our list of more than 300 publications:

03	Cardiovascular	15	Neurology	53	Respiratory
07	Dermatology	17	Obesity	55	Rheumatology
09	Endocrinology	18	Gynaecology	55	Surgery
11	Gastroenterology	18	Oncology	55	Urology
13	Pain	21	Ophthalmology	56	Health economics
13	Haematology	22	Orthopaedics	58	Other
15	Hepatology	23	Patient-reported outcomes		
15	Immunology	53	Psychiatry		

Publications

Cardiovascular

Verma, S., Leiter, L. A., Mangla, K. K., Nielsen, N. F., Hansen, Y., & Bonaca, M. P. (2024). Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review. *Diabetes Therapy*, 15(9), 1893-1961. <https://doi.org/10.1007/s13300-024-01606-6>

Pelletier-Galarneau, M., Cabra, A., Szabo, E., & Angadageri, S. (2024). Real-world evidence study on the impact of SPECT MPI, PET MPI, cCTA and stress echocardiography on downstream healthcare utilisation in patients with coronary artery disease in the US. *BMC Cardiovascular Disorders*, 24(1), 543. <https://doi.org/10.1186/s12872-024-04225-y>

Pelletier-Galarneau, M., Vandenbroucke, E., Lu, M., & Li, O. (2023). Characteristics and key differences between patient populations receiving imaging modalities for coronary artery disease diagnosis in the US. *BMC Cardiovascular Disorders*, 23(1), 251. <https://doi.org/10.1186/s12872-023-03218-7>

Gouëffic, Y., McWilliams, R., Burton, H., & Verin, N. (2023). Costs and Budget Impact of Collagen-Based Vascular Closure Device Versus Manual Compression Following Peripheral Endovascular Procedures. *Annals of Vascular Surgery*, 93, 64-70. <https://doi.org/https://doi.org/10.1016/j.avsg.2023.02.003>

Mancia, G., Cappuccio, F. P., Burnier, M., Coca, A., Persu, A., Borghi, C., Kreutz, R., & Sanner, B. (2023). Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension. *J Intern Med*, 294(3), 251-268. <https://doi.org/10.1111/joim.13678>

Menown, I., Montalescot, G., Pal, N., Fidler, C., Orme, M., & Gillard, S. (2010). Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. *Adv Ther*, 27(3), 181-191. <https://doi.org/10.1007/s12325-010-0013-x>

Mitchell S, O. M., Eckert L, Reynolds M. (2009). The effect of anti-arrhythmic drug therapy on all-cause and cardiovascular mortality in atrial fibrillation patients: a systematic review and meta-analysis. Presented at ISPOR 12th Annual European conference; Paris, France; October 24-27; 2009.

Menown I, J. A., Orme M, Gillard S. (2008). Clexane/Lovenox (enoxaparin) is a cost-effective adjunctive treatment to fibrinolysis for ST-elevation myocardial infarction (STEMI) compared with unfractionated heparin. *European Heart Journal*. 2008;29 (Abstract supplement P3546):568-9.

Ratcliffe A, B. T., Chambers M. (2006) . Economic Evaluation of Diagnostic Strategies in Patients with Suspected Coronary Artery Disease (CAD) in the UK. Presented at ISPOR 9th Annual European Congress; Copenhagen, Denmark; October 28-31; 2006.

Schachter, M., Mitchell, G., Niziol, C., & Abhyankar, B. A. (2003). Antihypertensive efficacy of moxonidine in primary care: a 'real-life' study. *Int J Clin Pract*, 57(6), 479-482.

Sullivan S, O. M., Morais E, Mitchell S. A systematic review and meta-analysis of randomised clinical trials reviewing anti-arrhythmic drugs for the treatment of atrial fibrillation. Presented at ISPOR 12th Annual European conference; Paris, France; October 24-27; 2009.

Sullivan, S. D., Orme, M. E., Morais, E., & Mitchell, S. A. (2013). Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis. *Int J Cardiol*, 165(2), 229-236. <https://doi.org/10.1016/j.ijcard.2012.03.070>

Turchetti, G., Kroes, M. A., Lorenzoni, V., Trieste, L., Chapman, A. M., Sweet, A. C., Wilson, G. I., & Neglia, D. (2015). The cost-effectiveness of diagnostic cardiac imaging for stable coronary artery disease. *Expert Rev Pharmacoecon Outcomes Res*, 15(4), 625-633. <https://doi.org/10.1586/14737167.2015.1051037>

Underwood SR, B. T., Basu S, Chambers M, Zyczynski T. (2008). An economic evaluation of myocardial perfusion scintigraphy in the diagnosis of coronary artery disease. Presented at ISPOR 11th Annual European conference; Athens, Greece; November 8-11; 2008.

Walley, T., Duggan, A. K., Haycox, A. R., & Niziol, C. J. (2003). Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. *J R Soc Med*, 96(11), 525-531. <https://doi.org/10.1177/014107680309601104>

Yohannes, A. M., & Willgoss, T. G. (2015). The accuracy of the anxiety inventory respiratory disease scale for patients with chronic obstructive pulmonary disease. *Int J Geriatr Psychiatry*, 30(1), 106-108. <https://doi.org/10.1002/gps.4202>

Fleming C, Chakraborty A, Jaiswal T, Patel P, & Nair S. (2021). Onset of Stroke in Patients with Post-COVID-19 Syndrome Following Hospitalisation for Severe COVID-19 Infection: A Systematic Literature Review. *ISPOR Abstract. Value in Health*, 24(12), S2.

LaVallee, C., Rascati, K. L., & Gums, T. H. (2020). Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. *J Clin Hypertens (Greenwich)*, 22(11), 2084-2092. <https://doi.org/10.1111/jch.14041>

Lovink A, L. F. Physician referral patterns for diagnostic imaging modality in CAD patients. Poster presented at ACC.20/World Congress of Cardiology, March 28-30, 2020.

Mamas, M. A., Tosh, J., Hulme, W., Hoskins, N., Bungey, G., Ludman, P., de Belder, M., Kwok, C. S., Verin, N., Kinnaird, T., Bennett, E., Curzen, N., Nolan, J., & Kontopantelis, E. (2018). Health Economic Analysis of Access Site Practice in England During Changes in Practice: Insights From the British Cardiovascular Interventional Society. *Circ Cardiovasc Qual Outcomes*, 11(5), e004482. <https://doi.org/10.1161/circoutcomes.117.004482>

Batson, S., Sutton, A., & Abrams, K. (2016). Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. *PLoS One*, 11(8), e0161864. <https://doi.org/10.1371/journal.pone.0161864>

Lip, G. Y., Mitchell, S. A., Liu, X., Liu, L. Z., Phatak, H., Kachroo, S., & Batson, S. (2016). Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. *Int J Cardiol*, 204, 88-94. <https://doi.org/10.1016/j.ijcard.2015.11.084>

Jakouloff D, S. T., Mitchell S, Raza S, Lockhart IA, Drost P. Heterogeneity in published evidence for stroke prevention in patients with atrial fibrillation: a systematic review. Presented at European Society of Cardiology Congress. Munich, Germany; August 25-29, 2012.

Freemantle, N., Lafuente-Lafuente, C., Mitchell, S., Eckert, L., & Reynolds, M. (2011). Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. *Europace*, 13(3), 329-345. <https://doi.org/10.1093/europace/euq450>

Barwell, P. A., Marelli C. (2008). Modelling the effect of diagnostic strategies in patients with suspected coronary artery disease (CAD) on capacity and productivity of coronary diagnostic facilities in the United Kingdom. Presented at ISPOR 11th Annual International Congress; Athens, Greece; November 8-11; 2008.

Hayes P, R. J., Jensen M, Harrison L, Brasseur P. (2008). Cost-effectiveness of endovascular aneurysm repair versus open surgical repair: acute infrarenal abdominal aortic aneurysm in an emergency setting. Presented at ISPOR 11th Annual European conference; Athens, Greece; November 8-11; 2008.

Duggan, A. K., & Niziol, C. J. (2003). Real-life treatment of hypertension in UK primary care: prescribing habits, results and adherence to clinical guidelines. *Br J Cardiol*, 10 (Suppl 3), S3-7.

Dermatology

Rengger L GP, Jowndla S, Daud S, Nair A, Nair S. (2024) Risk factors for psoriasis: an umbrella review of 12 published metanalyses. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Bungey, G., Chang-Douglass, S., Hsu, M. A., Cappelleri, J. C., Young, P., & Woolcott, J. (2020). Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. *J Manag Care Spec Pharm*, 26(8), 1027-1038. <https://doi.org/10.18553/jmcp.2020.19319>

Bungey G, C.-D. S., Hsu MA, Cappelleri JC, Young P, Woolcott J. (2018). Modeling the Costs and Outcomes Associated with Treatment Sequences, with and without Tofacitinib, for Moderately to Severely Active Psoriatic Arthritis in the US. Abstract 1264. *Arthritis Rheumatol*. 2018; 70 (suppl 10).

Gladman DD, O. A. M., Gomez-Reino J, Chang-Douglass S, Leoncini E, Burton HE, et al. (2018). Network Meta-Analysis of tofacitinib vs bDMARDs or apremilast for the treatment of TNF inhibitor-naïve patients with psoriatic arthritis. Poster THU0300. *Annals of the Rheumatic Diseases*. 2018;77:368-9.

Bungey G, W. N., Price K, O'Leary M. (2017). Economic Evaluation of Subcutaneous Methotrexate For Long-Term Treatment of Moderate-To-Severe Psoriasis In The United Kingdom. A549-A550 [PSY30]. *Value in Health*. October-November 2017;20(9).

Bungey G, C.-D. S., Erickson R, Katiyar J. (2017). Cost-Utility Analysis of Biological Therapies In Psoriasis Using Real World Evidence. A556 [PSY68]. *Value in Health*. October-November 2017;20(9).

Tolley, K., Kemmett, D., Thybo, S., Nasr, R., & Smethurst, H. (2016). A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. *Eur J Health Econ*, 17(3), 287-304. <https://doi.org/10.1007/s10198-015-0679-8>

Cawson, M. R., Mitchell, S. A., Knight, C., Wildey, H., Spurden, D., Bird, A., & Orme, M. E. (2014). Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. *BMC Musculoskelet Disord*, 15, 26. <https://doi.org/10.1186/1471-2474-15-26>

Healy, E., Bentley, A., Fidler, C., & Chambers, C. (2011). Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. *Br J Dermatol*, 164(2), 387-395. <https://doi.org/10.1111/j.1365-2133.2010.10141.x>

Svensson, A., Chambers, C., Gånemo, A., & Mitchell, S. A. (2011). A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. *Curr Med Res Opin*, 27(7), 1395-1406. <https://doi.org/10.1185/03007995.2011.582483>

Gillard, S. E., & Finlay, A. Y. (2005). Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. *Int J Clin Pract*, 59(11), 1260-1267. <https://doi.org/10.1111/j.1368-5031.2005.00680.x>

Barker J, G. S. (2004). Modelling the cost of methotrexate and cyclosporin treatment in psoriasis. Presented at 13th European Academy of Dermatology and Venereology Congress; Florence, Italy; November 17-21; 2004

O'Donnell RA, F. A., Niziol C. (2004). The impact of psoriasis on productivity; a survey of psoriasis patients in the United Kingdom. Presented at European Congress of Psoriasis; October 21-24; 2004:P043.

Gillard S, F. A., Niziol CJ. (2004) . Pharmaco-epidemiological analysis of 6,120 psoriasis patients in the United Kingdom. Presented at 9th International Congress of the International Society of Dermatology; Beijing, China; May 19-22; 2004.

Humphrey, K. M., Cork, M. J., & Haycox, A. (1998). A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. *Br J Dermatol*, 139(4), 660-664. <https://doi.org/10.1046/j.1365-2133.1998.02463.x>

Endocrinology

Kandalam, S., Benamar, M., Le Reun, C., Rengger, L., Gupta, P., & Nair, S. (2026). Efficacy and Safety of Once-Weekly IcoSema Versus Once-Daily IDegLira in People with Type 2 Diabetes: Systematic Literature Review and Network Meta-analysis. *Diabetes Ther.* <https://doi.org/10.1007/s13300-026-01847-7>

Chubb, B., Gupta, P., Gupta, J., Nuhoho, S., Kallenbach, K., & Orme, M. (2021). Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. *Diabetes Ther*, 12(5), 1325-1339. <https://doi.org/10.1007/s13300-021-01034-w>

Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang-Tan, T., & Paine, A. (2019). Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. *Diabetes Ther*, 10(6), 2183-2199. <https://doi.org/10.1007/s13300-019-00706-y>

Leelarathna, L., Ashley, D., Fidler, C., & Parekh, W. (2018). The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective. *Ther Adv Endocrinol Metab*, 9(7), 187-197. <https://doi.org/10.1177/2042018818766816>

Parekh, W., Streeton, S. E., Baker-Knight, J., Montagnoli, R., Nicoziani, P., & Marchesini, G. (2018). The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. *Diabetes Ther*, 9(3), 1037-1047. <https://doi.org/10.1007/s13300-018-0418-0>

Webb, N., Orme, M., Witkowski, M., Nakanishi, R., & Langer, J. (2018). A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes. *Diabetes Ther*, 9(3), 973-986. <https://doi.org/10.1007/s13300-018-0397-1>

Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018). A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin. *Diabetes Ther*, 9(3), 1233-1251. <https://doi.org/10.1007/s13300-018-0428-y>

- Hoskins, N., Tikkanen, C. K., & Pedersen-Bjergaard, U. (2017). The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool. *Journal of Medical Economics*, 20(4), 363-370. <https://doi.org/10.1080/13696998.2016.1269774>
- Bain, S. C., Witkowski, M. A., Hansen, B. B., Basse, A., & Mithal, A. (2016). Impact of Inadequate Insulin Resuspension (IIR) on Clinical, Patient And Economic Outcomes: A Systematic Literature Review. *Value in Health*, 19(7), A665-A666. <https://doi.org/10.1016/j.jval.2016.09.1835>
- Batson, S., & Burton, H. (2016). A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus. *PLoS One*, 11(10), e0164827. <https://doi.org/10.1371/journal.pone.0164827>
- Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016). Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. *Diabetes Ther*, 7(1), 45-60. <https://doi.org/10.1007/s13300-016-0157-z>
- Parekh, W. A., Ashley, D., Chubb, B., Gillies, H., & Evans, M. (2015). Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool. *Diabet Med*, 32(9), 1156-1166. <https://doi.org/10.1111/dme.12771>
- Fidler, C., Elmelund Christensen, T., & Gillard, S. (2011). Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. *J Med Econ*, 14(5), 646-655. <https://doi.org/10.3111/13696998.2011.610852>
- Christensen, T., Buckland, A., Bentley, A., Djurhuus, C., & Baker-Searle, R. (2010). Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. *Clin Ther*, 32(6), 1068-1082. <https://doi.org/10.1016/j.clinthera.2010.05.012>
- Christensen, T., Fidler, C., Bentley, A., & Djurhuus, C. (2010). The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden. *Journal of Medical Economics*, 13(1), 168-178. <https://doi.org/10.3111/13696991003652248>
- Bech PG, B. A., Bentley A, Twena N, Christensen T. (2008). Cost-effectiveness of somatropin (Norditropin®) for the treatment of growth hormone deficient (GHD) children in a Swedish setting. Presented at ISPOR 13th Annual International Congress; Toronto, ON Canada; May 3-7; 2008.

Christensen TL, B. A., Bentley A, Djuurhas C, Twena N. (2008) Economic evaluation of somatropin (Norditropin®) for the treatment of short children born small for gestational age (SGA) in Sweden. Presented at 4th International Congress of the GRS and the IGF Society; Genova, Italy; September 16-20; 2008.

Elia, M., Ceriello, A., Laube, H., Sinclair, A. J., Engfer, M., & Stratton, R. J. (2005). Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: a systematic review and meta-analysis. *Diabetes Care*, 28(9), 2267-2279. <https://doi.org/10.2337/diacare.28.9.2267>

Bottomley, J., Duggan, A. K., & Williams, R. (2002). Health care needs diabetes model – description of a practical tool. *Pract Diab Int*, 19(7), 206–210.

Gastroenterology

Hashim S, Wang S, Burr B, Tadwalkar S, Mehta R, Gupta A. (2025) Treatment of Irritable Bowel Syndrome With Antispasmodics in Taiwan, Hong Kong, and Vietnam: A Delphi Expert Consensus Statement. *J Neurogastroenterol Motil*. 2025 Oct 30;31(4):512-26. <https://doi.org/10.5056/jnm25035>

Hashim S XQ, Wang S, Isherwood A, Burr B, Blandy O, Massey R. (2024) Heterogeneity in Crohn's disease and Ulcerative Colitis clinical endpoints leading to uncertainties in the real-world setting. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Agrawal, M., Spencer, E. A., Colombel, J. F., & Ungaro, R. C. (2021). Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. *Gastroenterology*, 161(1), 47-65. <https://doi.org/10.1053/j.gastro.2021.04.063>

Szczubelek, M., Pomorska, K., Korolczyk-Kowalczyk, M., Lewandowski, K., Kaniewska, M., & Rydzewska, G. (2021). Effectiveness of Crohn's Disease Exclusion Diet for Induction of Remission in Crohn's Disease Adult Patients. *Nutrients*, 13(11). <https://doi.org/10.3390/nu13114112>

Sigall Boneh, R., Van Limbergen, J., Wine, E., Assa, A., Shaoul, R., Milman, P., Cohen, S., Kori, M., Peleg, S., On, A., Shamaly, H., Abramias, L., & Levine, A. (2021). Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease. *Clin Gastroenterol Hepatol*, 19(4), 752-759. <https://doi.org/10.1016/j.cgh.2020.04.006>

LaVallee C, Seelam P, Balakrishnan S, Lowen C, Henrikson A, Kesting B, & Torres, K. A. (2020). Real-World Evidence Investigation of Tolerance, Healthcare Utilization, and Cost of Enteral Peptide-Based Diets in Pediatric Patients in Post-Acute Care in the United States. *J Parenter Enteral Nutr*, 44(2), 382.

LaVallee C, Seelam P, Balakrishnan S, Lowen C, Henrikson A, Kesting B, & Torres, K. A. (2019). Real-World Evidence Investigation of Clinical Characteristics and Tolerance Outcomes of Enteral Peptide-Based Diets in Pediatric Patients in Post-Acute Care in the United States. *Journal of Pediatric Gastroenterology and Nutrition*, 69(pS291).

Burton, H. E., Mitchell, S. A., & Watt, M. (2017). A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for *Clostridium difficile* Infection. *Pharmacoeconomics*, 35(11), 1123-1140. <https://doi.org/10.1007/s40273-017-0540-2>

Lindsay, J. O., Bergman, A., Patel, A. S., Alesso, S. M., & Peyrin-Biroulet, L. (2015). Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. *Aliment Pharmacol Ther*, 41(11), 1066-1078. <https://doi.org/10.1111/apt.13197>

Elia, M., Engfer, M. B., Green, C. J., & Silk, D. B. (2008). Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae. *Aliment Pharmacol Ther*, 27(2), 120-145. <https://doi.org/10.1111/j.1365-2036.2007.03544.x>

Buckland, A., & Bodger, K. (2008). The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. *Aliment Pharmacol Ther*, 28(11-12), 1287-1296. <https://doi.org/10.1111/j.1365-2036.2008.03856.x>

Stratton, R. J., Ek, A. C., Engfer, M., Moore, Z., Rigby, P., Wolfe, R., & Elia, M. (2005). Enteral nutritional support in prevention and treatment of pressure ulcers: a systematic review and meta-analysis. *Ageing Res Rev*, 4(3), 422-450. <https://doi.org/10.1016/j.arr.2005.03.005>

Haycox, A., Howard, S. P., Partridge, A., & Wright, T. (2001). A comparison of evidence and practice in the treatment of constipation. *J Med Econ*, 4, 91-98.

Duggan, A. K. (1998). Modelling different approaches to the management of upper gastrointestinal disease. *Pharmacoeconomics*, 14 Suppl 2, 25-37. <https://doi.org/10.2165/00019053-199814002-00004>

Pain

Ho KY, Nagrale D, Chuchai PK, De Leon JR, Koh-Cabaluna LJ, Mokhtar SA, et al. (2025). Opportunities for Shared Decision-Making in the Management of Acute Pain in Asia-Pacific Countries. *Cureus*. 2025 Oct;17(10):e95305. <https://doi.org/10.7759/cureus.95305>

Patel, A. S., Farquharson, R., Carroll, D., Moore, A., Phillips, C. J., Taylor, R. S., & Barden, J. (2012). The impact and burden of chronic pain in the workplace: a qualitative systematic review. *Pain Pract*, 12(7), 578-589. <https://doi.org/10.1111/j.1533-2500.2012.00547.x>

Phillips, C. J., & Harper, C. (2011). The economics associated with persistent pain. *Curr Opin Support Palliat Care*, 5(2), 127-130. <https://doi.org/10.1097/SPC.0b013e3283458fa9>

Duggan, A. K. (1995). The cost of analgesia for moderate to severe pain in General Practice. *Br J Med Econ*, 9, 99-106.

Duggan, A. K. (1995). The cost of constipation in morphine patients and the economic possibilities with tramadol. *Br J Med Econ*, 9, 21-29.

Duggan, A. K. (1995). The cost of managing post-operative pain with intravenous tramadol compared with epidural morphine. *Br J Med Econ*, 9, 37-40.

Duggan, A. K. (1995). The cost of managing post-operative pain: a comparison of tramadol and morphine. *Br J Med Econ*, 9, 59-66.

Duggan, A. K. (1995). Pharmacoeconomic aspects of the use of tramadol hydrochloride. *Rev Contemp Pharmacother*, 6(10), 541-545.

Haematology

LaVallee, C., Bansal, I., Kamdar, S., Kwong, W. J., & Boccia, R. V. (2022). Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis. *J Blood Med*, 13, 133-142. <https://doi.org/10.2147/jbm.S349070>

Benson G, Morton T, Thomas H, & Lee YY. (2020) Long-term outcomes of previously-treated adult and adolescent patients with severe haemophilia a receiving prophylaxis with extended half-life FVIII treatments- An economic analysis from a UK Perspective. PRO38. Presented at Virtual ISPOR Europe. Milan, Italy, November 16-19; 2020.

LaVallee C, Cronin P, Bansal I, Kwong W J, & Boccia R V. (2020). Effectiveness of Parenteral Iron Therapy in the Real-world Setting: A Retrospective Analysis. *Journal of Clinical Haematology*, 1(1), 16-25.

Dalal, M., Mitchell, S., McCloskey, C., Zagadailov, E., & Gautam, A. (2017). The Risk-Benefit Balance of Treatments for Hodgkin Lymphoma Reported in the Randomised and Non-Randomised Trial Setting: A Systematic Review. *Blood*, 130(Supplement 1), 5605-5605. https://doi.org/10.1182/blood.V130.Suppl_1.5605.5605

Pepe, A., Rossi, G., Bentley, A., Putti, M. C., Frizziero, L., D'Ascola, D. G., Cuccia, L., Spasiano, A., Filosa, A., Caruso, V., Hanif, A., & Meloni, A. (2017). Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β -Thalassaemia Major Patients: An Italian Perspective. *Clin Drug Investig*, 37(5), 453-464. <https://doi.org/10.1007/s40261-017-0496-1>

Cohen, A., Batson, S., Hamilton, M., Masseria, C., Mitchell, S., & Phatak, H. (2015). Comparison of oral anticoagulants or antiplatelet therapy for the extended treatment of venous thromboembolism: systematic review and network meta-analysis. *Journal of the American College of Cardiology*, 65(10_Supplement), A2086-A2086. [https://doi.org/10.1016/S0735-1097\(15\)62086-1](https://doi.org/10.1016/S0735-1097(15)62086-1)

Cohen, A. T., Hamilton, M., Mitchell, S. A., Phatak, H., Liu, X., Bird, A., Tushabe, D., & Batson, S. (2015). Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. *PLoS One*, 10(12), e0144856. <https://doi.org/10.1371/journal.pone.0144856>

Dolan, G., Smith, L. A., Collins, S., & Plumb, J. M. (2008). Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. *Curr Med Res Opin*, 24(5), 1459-1472. <https://doi.org/10.1185/030079908x297349>

Riedler GF, D. H. (2004). "Serious hazards of transfusion" underestimates the incidence of transfusion-related acute lung injury in the UK. *Vox Sang*. 2004;86(4):268.

Hepatology

Younossi, Z., Aggarwal, P., Shrestha, I., Fernandes, J., Johansen, P., Augusto, M., & Nair, S. (2022). The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. *JHEP Rep*, 4(9), 100525. <https://doi.org/10.1016/j.jhepr.2022.100525>

Johansen, P., Howard, D., Bishop, R., Moreno, S. I., & Buchholtz, K. (2020). Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. *Pharmacoeconomics*, 38(5), 485-497. <https://doi.org/10.1007/s40273-019-00881-7>

Immunology

Recto M, Chantaphakul H, Woo K, Lao-araya M, Ling W, Lobo R, et al. (2026). Asian Experiences in Treating School-Age Children with Bilastine 10 mg Orodispersible Tablets: Cases from Clinical Practice. *Frontiers in Medical Case Reports*. 2026 01/01;07:01-16.

Kumar V, Thakker D, Gupta P, & Nair S. (2021). Management of patients with deficiency of adenosine deaminase-2 (DADA2): A systematic literature review. *ISPOR Abstract*. *Value in Health*, 24(12), S2.

Hill, D. J., Murch, S. H., Rafferty, K., Wallis, P., & Green, C. J. (2007). The efficacy of amino acid-based formulas in relieving the symptoms of cow's milk allergy: a systematic review. *Clin Exp Allergy*, 37(6), 808-822. <https://doi.org/10.1111/j.1365-2222.2007.02724.x>

Neurology

Weidlich, D., Servais, L., Kausar, I., Howells, R., & Bischof, M. (2023). Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England. *Neurol Ther*, 12(4), 1205-1220. <https://doi.org/10.1007/s40120-023-00489-2>

Dean, R., Dabbous, O., Weidlich, D., & Bischof, M. (2022). Body of Evidence for Onasemnogene Apeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse. *Value Health*, 25(11), 1922-1923. <https://doi.org/10.1016/j.jval.2021.10.019>

Bischof, M., Lorenzi, M., Lee, J., Druyts, E., Balijepalli, C., & Dabbous, O. (2021). Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. *Curr Med Res Opin*, 37(10), 1719-1730. <https://doi.org/10.1080/03007995.2021.1947216>

McCloskey C, Premshakar A, Shet A, Toboso Ortega M, & Nair S. (2021). Correlation of amyloid levels and cognitive impairment in patients with Alzheimer's disease: a systematic literature review and meta-analysis. *ISPOR Abstract. Value in Health*, 24(12), S2.

Shet A, Kohli AS, Gupta P, & Nair S. (2021). Incidence of Guillan-Barré Syndrome in Europe: A targeted literature review. *ISPOR Abstract. Value in Health*, 24(12), S2.

Choy, E., Marshall, D., Gabriel, Z. L., Mitchell, S. A., Gylee, E., & Dakin, H. A. (2011). A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. *Semin Arthritis Rheum*, 41(3), 335-345.e336. <https://doi.org/10.1016/j.semarthrit.2011.06.003>

Kroes M, G.-S. S., Allen F, Eyssen M, Paulus D. (2011). Dementia: which non-pharmacological interventions? KCE reports 160C. https://kce.fgov.be/sites/default/files/page_documents/kce_160c_dementia_0.pdf

Lockhart, I. A., Orme, M. E., & Mitchell, S. A. (2011). The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. *Dement Geriatr Cogn Dis Extra*, 1(1), 212-227. <https://doi.org/10.1159/000330032>

Dangour, A. D., Whitehouse, P. J., Rafferty, K., Mitchell, S. A., Smith, L., Hawkesworth, S., & Vellas, B. (2010). B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. *J Alzheimers Dis*, 22(1), 205-224. <https://doi.org/10.3233/jad-2010-090940>

Liedgens, H., Hertel, N., Gabriel, A., Nuijten, M., Dakin, H., Mitchell, S., & Nautrup, B. P. (2008). Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. *Clin Drug Investig*, 28(9), 583-601. <https://doi.org/10.2165/00044011-200828090-00005>

Dakin, H., Nuijten, M., Liedgens, H., & Nautrup, B. P. (2007). Cost-Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. *Clinical Therapeutics*, 29(7), 1491-1507. <https://doi.org/10.1016/j.clinthera.2007.07.006>

Dakin HA, N. M., Liedgens H, Poulsen Nautrup B. (2007). Cost-utility analysis evaluating lidocaine 5% medicated plaster relative to gabapentin for post-herpetic neuralgia in Scotland. Podium presentation at ISPOR 12th Annual International Meeting; Arlington, Virginia; May 19-23; 2007.

Dakin HA, N. M., Poulsen Nautrup B, Liedgens H. (2007). Cost-effectiveness of a lidocaine plaster relative to pregabalin in the treatment of post-herpetic neuralgia in Scotland. Podium presentation at ISPOR 10th Annual European Congress; Dublin, Ireland; October 20-23; 2007.

Liedgens H, H. N., Gabriel A, Nuijten MJC, Dakin HA, Spöhrer U. (2007). Cost-utility analysis evaluating the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in Germany. Poster presentation at ISPOR 10th Annual European Congress PND20; Dublin, Ireland; October 20-23; 2007.

Ward, A., Roberts, G., Warner, J., & Gillard, S. (2005). Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. *J Rehabil Med*, 37(4), 252-257. <https://doi.org/10.1080/16501970510027312>

Obesity

Kanu C, Al-Zubeidi T, Shinde S, Al-Jassar G, Poon JL, Miller J, et al. (2026) Understanding the patient experience of heart failure with obesity and preserved ejection fraction (HFpEF): qualitative insights from patients and clinicians. *Journal of Patient-Reported Outcomes*. 2026 2026/01/21. doi: [10.1186/s41687-026-00998-2](https://doi.org/10.1186/s41687-026-00998-2)

Nather, K., Bolger, F., DiModica, L., Fletcher-Louis, M., Salvador, J., Pattou, F., Panton, U. H., & Cancino, A. P. (2021). The impact of COVID-19 on obesity services across Europe: A physician survey. *Clin Obes*, e12474. <https://doi.org/10.1111/cob.12474>

Gynaecology

Ashkenazy R, K. V., Leoncini E, Wing-Yu Tang, Trigg A, Webb N. (2017). Clinical, demographic, and physician-related factors associated with women's adherence to premarin (conjugated estrogens) vaginal cream: findings from a large, US based, observational, real-world database. Poster presented at the North American Menopause Society Annual Meeting, October 11-14, 2017 Philadelphia, USA.

Harrison L. (2005). Abacus International Survey. Survey measuring the impact of NICE Guideline 11: Fertility – assessment and treatment for people with fertility problems. Survey One: PCT Commissioning Managers.

Harrison L. (2005). Abacus International Survey. A survey measuring the impact of NICE Guideline 11: Fertility – assessment and treatment for people with fertility problems. Survey Two: Fertility Experts.

Oncology

Rengger et al. (2025). Drivers of Improvement in Observed Survival in Malignant Cancer Sites: A Cancer Registry Analysis. Poster presented at ISPOR EU 2025, Glasgow. 2025.

Isherwood A et al. (2025). Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and EHR, Population Census, and Cancer Registry Data in the United States. Poster presented at ISPOR EU 2025, Glasgow. 2025.

Isherwood A, Bolger F, Morris J, Rollmann D, Griffin A, Spencer M, Hickson S. (2025). EPH224 Survival Trends in Multiple Myeloma by Treatment Era in the United States. Value in Health. 2025. <https://doi.org/10.1016/j.jval.2025.09.1353>

Ramos García, L., & Webster, R. M. (2024). The colorectal cancer drug market. Nat Rev Drug Discov. <https://doi.org/10.1038/d41573-024-00026-2>

Tur, J., & Webster, R. M. (2024). The renal cell carcinoma drug market. Nat Rev Drug Discov, 23(1), 16-17. <https://doi.org/10.1038/d41573-023-00186-7>

Barcena L MC, Kalakonda S, Musku K, Nair S. (2024) Gene therapies for high grade gliomas and glioblastomas: a systematic review. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Nawaz, K., & Webster, R. M. (2023). The non-small-cell lung cancer drug market. *Nat Rev Drug Discov*. <https://doi.org/10.1038/d41573-023-00017-9>

McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2022). A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. *Pharmacoecon Open*, 1-34. <https://doi.org/10.1007/s41669-022-00361-3>

García-Alfonso, P., Lièvre, A., Loupakis, F., Tadmouri, A., Khan, S., Barcena, L., & Stintzing, S. (2022). Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF(V600E)-mutant metastatic and/or unresectable colorectal cancer. *Crit Rev Oncol Hematol*, 173, 103646. <https://doi.org/10.1016/j.critrevonc.2022.103646>

Thureson, P. O., Vander Velde, N., Gupta, P., & Talbot, J. (2020). A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma. *Adv Ther*, 37(12), 4877-4893. <https://doi.org/10.1007/s12325-020-01507-7>

Cooper, K., Tappenden, P., Cantrell, A., & Ennis, K. (2020). A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer. *Br J Cancer*, 123(11), 1686-1696. <https://doi.org/10.1038/s41416-020-01050-w>

Dalal, M., Mitchell, S., McCloskey, C., Zagadailov, E., & Gautam, A. (2020). The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. *Expert Rev Hematol*, 13(4), 405-419. <https://doi.org/10.1080/17474086.2020.1717945>

Burton H, & Harvey R. (2019). Fractional polynomial models for network meta-analysis of survival data in economic evaluations: A case-study on the cost-effectiveness of fulvestrant in previously-treated postmenopausal, oestrogen receptor-positive advanced breast cancer. *ISPOR Abstract PCN 198*. *Value in Health*, 22, S474.

Eccleston, A., Bentley, A., Dyer, M., Strydom, A., Vereecken, W., George, A., & Rahman, N. (2017). A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. *Value Health*, 20(4), 567-576. <https://doi.org/10.1016/j.jval.2017.01.004>

Puglisi, F., Rea, D., Kroes, M. A., & Pronzato, P. (2016). Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. *Cancer Treat Rev*, 43, 36-49. <https://doi.org/10.1016/j.ctrv.2015.11.012>

Telford, C., Jones, N., Livings, C., & Batson, S. (2016). Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. *Clin Breast Cancer*, 16(3), 188-195. <https://doi.org/10.1016/j.clbc.2016.02.007>

Valle, J. W., Eatock, M., Clueit, B., Gabriel, Z., Ferdinand, R., & Mitchell, S. (2014). A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. *Cancer Treatment Reviews*, 40(3), 376-389. <https://doi.org/https://doi.org/10.1016/j.ctrv.2013.08.007>

Larkin, J., Paine, A., Tumor, I., Cappelleri, J. C., Healey, P. J., Sr., Foley, G., Mitchell, S., Kroes, M., & Chen, C. (2013). Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. *Expert Opin Pharmacother*, 14(1), 27-39. <https://doi.org/10.1517/14656566.2013.758713>

Ferdinand, R., Mitchell, S. A., Batson, S., & Tumor, I. (2012). Treatments for chronic myeloid leukemia: a qualitative systematic review. *J Blood Med*, 3, 51-76. <https://doi.org/10.2147/jbm.S33380>

Elia, M., Van Bokhorst-de van der Schueren, M. A., Garvey, J., Goedhart, A., Lundholm, K., Nitenberg, G., & Stratton, R. J. (2006). Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. *Int J Oncol*, 28(1), 5-23. <https://doi.org/10.3892/ijo.28.1.5>

Kübler, A., Niziol, C., Sidhu, M., Dünne, A., & Werner, J. A. (2005). [Analysis of cost effectiveness of photodynamic therapy with Foscan (Foscan-PDT) in comparison with palliative chemotherapy in patients with advanced head-neck tumors in Germany]. *Laryngorhinootologie*, 84(10), 725-732. <https://doi.org/10.1055/s-2005-861048> (Eine Kosten-Effektivitäts-Analyse der photodynamischen Therapie mit Foscan (Foscan-PDT) im Vergleich zu einer palliativen Chemotherapie bei Patienten mit fortgeschrittenen Kopf-Halstumoren in Deutschland.)

Ophthalmology

Kowalski, J. W., Hayward, E., Mazzi, S., Pardhanani, G., Almond, C. M., Trueman, D., & Adena, M. A. (2012). Valutazione economica del trattamento con impianto intravitreale biodegradabile di desametasone di pazienti affetti da edema maculare secondario a occlusione della vena retinica, in Italia. *PharmacoEconomics Italian Research Articles*, 14(1), 29-38. <https://doi.org/10.1007/BF03320692>

Orme, M., Collins, S., & Loftus, J. (2012). Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches. *J Glaucoma*, 21(7), 433-449. <https://doi.org/10.1097/IJG.0b013e31821dac2a>

Dakin, H. A., Welton, N. J., Ades, A. E., Collins, S., Orme, M., & Kelly, S. (2011). Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. *Stat Med*, 30(20), 2511-2535. <https://doi.org/10.1002/sim.4284>

Hayward, E., Almond, C., Trueman, D., Yeh, W. S., & Kowalski, J. W. (2011). PSS25 the Cost-Effectiveness of Ozurdex® (Dexamethasone Intravitreal Implant in Applicator) Compared With Observation for the Treatment of Macular Oedema Following Central and Branch Retinal Vein Occlusion. *Value in Health*, 14(7), A506. <https://doi.org/10.1016/j.jval.2011.08.1490>

Orme, M., Collins, S., Dakin, H., Kelly, S., & Loftus, J. (2010). Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. *Curr Med Res Opin*, 26(3), 511-528. <https://doi.org/10.1185/03007990903498786>

Orme M, L. J., Collin S. (2008). Modelling the long-term clinical outcomes of medical management of primary open angle glaucoma and ocular hypertension. Presented at ISPOR 11th Annual European conference; Athens, Greece; November 8-11; 2008.

Orme M, L. J., Collin S, Kelly S. (2008). A mixed treatment comparison of topical and ocular hypertensives for the treatment of glaucoma and ocular hypertension. Presented at ISPOR 11th Annual European conference; Athens, Greece; November 8-11; 2008.

Roberts G, B. P., Holmstrom S, Finck K, Gillard S, Warner J. (2003). Comparison of the clinical and cost effectiveness of Lumigan and Xalatan, in the treatment of glaucoma. *Value Health*. 2003;6(6):PAE10.

Orthopaedics

Frappier, J., Stanish, W., Brittberg, M., Steinwachs, M., Crowe, L., Castelo, D., & Restrepo, A. (2014). Economic evaluation of BST-CarGel as an adjunct to microfracture vs microfracture alone in knee cartilage surgery. *J Med Econ*, 17(4), 266-278. <https://doi.org/10.3111/13696998.2014.897626>

Cohen, A., Drost, P., Marchant, N., Mitchell, S., Orme, M., Rublee, D., Simon, T. A., & Sutton, A. (2012). The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. *Clin Appl Thromb Hemost*, 18(6), 611-627. <https://doi.org/10.1177/1076029612437579>

Cohen A, M. N., Mitchell S, Orme M, Rublee D, Simon T. (2011). The efficacy and safety of pharmacological prophylaxis of VTE following elective knee or hip replacement: systematic review and network meta-analysis. Presented at American Society of Hematology (ASH) 53rd Annual Meeting; San Diego, California; December 10-13; 2011.

Kemler, M. A., Raphael, J. H., Bentley, A., & Taylor, R. S. (2010). The cost-effectiveness of spinal cord stimulation for complex regional pain syndrome. *Value Health*, 13(6), 735-742. <https://doi.org/10.1111/j.1524-4733.2010.00744.x>

Alt, V., Donell, S. T., Chhabra, A., Bentley, A., Eicher, A., & Schnettler, R. (2009). A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France. *Injury*, 40(12), 1269-1275. <https://doi.org/10.1016/j.injury.2009.02.007>

Buckland AG, P. J. (2008) Cost-Effectiveness of Hip Resurfacing in Younger Adults in the United States. *Journal of Managed Care Medicine*. 11(4):25-32.

Richardson JB, B. T., Barnes DC, Buckland AG, Posnett J. (2005). Metal on metal (MoM) hip resurfacing (Birmingham Hip Resurfacing [BHR]) in young patients with severe hip damage - A cost utility analysis. *Value in Health*. 8(6):A24 (Abstract PAR2).

Patient-reported outcomes

Kanu C, Al-Zubeidi T, Shinde S, Al-Jassar G, Poon JL, Miller J, et al. (2026) Understanding the patient experience of heart failure with obesity and preserved ejection fraction (HFpEF): qualitative insights from patients and clinicians. *Journal of Patient-Reported Outcomes*. 2026 2026/01/21. doi: [10.1186/s41687-026-00998-2](https://doi.org/10.1186/s41687-026-00998-2)

Carmichael, C., Gousset, C., Burns, D., Miller, J., Van Tomme, S., Kitchen, H., Makin, H., Aldhouse, N., & Cordero, P. (2025). Fatigue Experience in Oncology; a Targeted Qualitative Literature Review and Novel Patient-Centric Conceptual Model. *Adv Ther*. <https://doi.org/10.1007/s12325-025-03330-4>

Lv, et al. (2025). Experiences of patient and care partner dyads in early Alzheimer's disease: a mixed-method study in the United States. *Neurodegenerative Disease Management*, 1-12. <https://doi.org/10.1080/17582024.2025.2542700>

Xenakis et al. (2025). Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM). Accepted at ACR Convergence 2025, 24-29 October 2025, Chicago Illinois.

Yi et al. (2025). Content validation of patient-reported outcome (PRO) measures for fatigue, physical function impacts, and skin symptoms in adult Dermatomyositis (DM). Accepted at EADV Congress 2025, 17-20 September 2025, Paris, France.

LaMarca et al. (2025). The Patient Experience of Living with LGMD2A/R1: Findings from a Focus Group. Accepted at the 2025 International Limb Girdle Muscular Dystrophy Conference, July 19 2025, Florida, US.

Aldhouse et al. (2025). Towards Patient-Centric Asthma Endpoints: A Targeted Review of Exacerbation, Control, and Remission Concepts. Accepted at ATS, May 18-21 2025, San Francisco, US.

Kanu et al. (2025). The Patient Experience of Living With Knee Osteoarthritis Pain: Development of a Conceptual Model. *Musculoskeletal Care*, 23(2), e70133. <https://doi.org/10.1002/msc.70133>

Wong et al. (2025). Requirements for Patient-Reported Outcome and Data Analytics in Health Technology Assessment in England, France and Germany, and Opportunities for Methods Harmonization across European Markets. Accepted at ISPOR US Annual Conference, May 13-16 2025, Montreal, Canada.

Carmichael et al. (2025a). Patient Experience of Crohn's Disease: A Conceptual Model Based on Qualitative Interviews. Accepted at ISPOR US Annual Conference, May 13-16 2025, Montreal, Canada.

McKee et al. (2025). Patient Experience of Ulcerative Colitis: A Conceptual Model Based on Qualitative Interviews. Accepted at ISPOR US Annual Conference, May 13-16 2025, Montreal, Canada.

Carmichael et al. (2025b). Patient Experience of Treatment with Tirzepatide for Weight Management: Exit Interviews from SURMOUNT-4. The Patient-Patient-Centered Outcomes Research. 2025 Feb 22:1-2.

Toumi, M., Wallace, J., Cohen, C., Marshall, C., Kitchen, H., Macey, J., Pegram, H., Slagle, A. F., Gish, R. G., Ning, Q., Yatsuhashi, H., Cornberg, M., Brunetto, M., van Bömmel, F., Xie, Q., Lee, D., Habuka, N., Sbarigia, U., Beumont-Mauviel, M, Wang, S. (2024). Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States. BMC Public Health, 24(1), 611. <https://doi.org/10.1186/s12889-023-17263-6>

Ford, D. M., Lawton, R., Travis, E., Teale, E. A., & O'Connor, D. B. (2024). Development and initial validation of a hospital stress questionnaire. Health Psychology and Behavioral Medicine, 12(1). <https://doi.org/10.1080/21642850.2024.2396135>

Trudeau, et al. (2025). Exploring the role of digital health technologies in assessing functional mobility and physical activity: Insights from qualitative interviews in adults with obesity or overweight. Obesity Pillars. 2025 2025/12/01/;16:100214.

Secinti, et al. (2025). Development of a Conceptual Model of the Patient Experience of Alcohol Use Disorder (AUD) - a Targeted Qualitative Literature Review. American Academy of Addiction Psychiatry (AAP) 36th Annual Meeting, 6-9 November 2025, San Francisco, US. . 2025.

Collins, et al. (2025). Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews. Presented at ISPOR Europe 2025, 9-12 November 2025, Glasgow, Scotland. 2025.

Carmichael, et al. (2025). PCR45 Cognitive Debrief of the PROMIS Parent Proxy Mobility Item Bank in Caregivers of Children Living With Duchenne Muscular Dystrophy. *Value in Health*. 2025;28(12):S554.

Carmichael, et al. (2025). PCR168 Pain and Fatigue Assessment and Evaluation in Oncology Trials. *Value in Health*. 2025;28(12):S580.

Newton, et al. (2025). CO72 Development of a Preliminary Conceptual Model to Capture the Adult Patient Experience of Follicular Lymphoma. *Value in Health*. 2025;28(12):S56.

Knight S, et al. (2025). PCR90 Exploring Beyond the Gut: A Qualitative Study of Extraintestinal Symptoms in Ulcerative Colitis and Crohn's Disease. *Value in Health*. 2025;28(12):S565.

Bottomley C, Knight S. (2025) PCR9 A Review of Approaches to Select Instruments and Items to Measure Patient Reported Tolerability in Clinical Trials in Oncology. *Value in Health*. 2025;28(12):S548.

Macey, et al. (2025). Collecting, Analyzing and Reporting Concept Elicitation Data using Content Analysis for Concept Elicitation (CACE) to Select or Develop Clinical Outcome Assessment (COA) Measures. Presented at ISOQOL 2025, 22-25 October 2025, Milwaukee, US. 2025.

Macey, et al. (2025). Patient perspectives and experiences related to interviewing methodology for clinical outcomes assessment research. Presented at ISOQOL 2025, 22-25 October 2025, Milwaukee, US. 2025.

Burn, et al. (2025). Can AI contribute to the development of a conceptual model of the patient experience? A feasibility assessment. Presented at ISOQOL 2025, 22-25 October 2025, Milwaukee, US. 2025.

Carmichael, et al. (2025). Pain Experience in Oncology: A Targeted Literature Review and Development of a Novel Patient-Centric Conceptual Model. *Cancers (Basel)*. 2025 Nov 25;17(23). doi:10.3390/cancers17233760

Gibble TH, Macey J, Makin H, Rosu R, Mellor K, Kitchen H, Carlier H, Dubinsky MC. P720 Exit interviews exploring Crohn's disease patients' experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease. *Journal of Crohn's and Colitis*. 2024 Jan 1;18(Supplement_1):i1353-4

Stander S, Kim BS, Guillemin I, Rhoten S, Wratten S, Brookes E, O'Malley JT, Bansal A, Msihid J, Thomas R, Bahloul D. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis. *Journal of the European Academy of Dermatology and Venereology*, 2024, 00, 1-9

Barthelmes J MK, Borsi A, Marshall C. Targeted literature review to explore the patient experience of hemolytic disease of the foetus and newborn (HDFN). Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Carmichael C, Kitchen H, McKee S, Audhya I, Patel S, Iff J, Muntoni F, Henricson E, Lowes L. Development of a conceptual model of the patient experience of Duchenne muscular dystrophy (DMD) through qualitative interviews. Presented at Neuromuscular Study Group (NMSG) Annual Scientific Meeting, September 20 2024, Tarrytown, NY.

Carmichael et al. (2024). How do we know if a concept is salient to the patient experience? A review of qualitative interview and analysis techniques in concept elicitation studies. Accepted at ISOQOL 2024 Annual Conference, October 13-16 2024. Cologne, Germany.

Collins et al. (2024). Qualitative Insights on Meaningful Change in Physical Functioning in SURMOUNT-4 Participants. *Endocrine Practice*. 2024 May 1;30(5):S71

Jouravskaya I, Kanu C, Ling Poon J, Mojdami D, Collins E, Burns DS, Kitchen H, Carmichael C. Patient Experiences with Tirzepatide in SURMOUNT-4. *Diabetes*. 2024 Jun 14;73(Supplement_1)

Kanu C, Al-Zubeidi T, Shinde S, Al-Jassar G, Ling Poon J, Miller J, Marshall C, Carmichael C. Understanding the Patient Experience of Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity—Qualitative Insights from Patients and Clinicians. *Diabetes*. 2024 Jun 14;73(Supplement_1)

Scippa et al. (2024). Recognizing Unmet Need in Chronic Inflammatory Demyelinating Polyneuropathy: Development of a Conceptual Model Characterizing Patient Experiences and Perspectives. Poster presented at American Academy of Neurology 2024 Annual Meeting, April 13-18 2024, Denver, CO, USA.

Knight et al. (2024). Poster FRPO871: Conceptual Model of the Patient Experience of IgAN: A Qualitative Literature Review and Model Update. Presented at ASN Kidney Week, 25th October 2024, San Diego

Lucats et al. (2024). Prioritizing Patient Perspectives: Identifying Key Symptoms in Crohn's Disease and Ulcerative Colitis to Enhance Clinical Trial Design. Accepted at 32nd United European Gastroenterology Week (UEG Week), October 12-15 2024, Vienna, Austria

Macey et al. (2024). Understanding the Participant Experience of Qualitative Interview Studies To Inform Future Study Design: Analysis of Feedback Forms. Poster presented at ISPOR 2024, May 5–8 2024, Atlanta, GA, US

McKee, S., Xenakis, J., Makin, H., Marshall, C., Winette, R., Aggarwal, R., Knight, S. Cutaneous Manifestations in Patients with Dermatomyositis, Are They Only Skin Deep?. *Dermatol Ther (Heidelb)* (2024). <https://doi.org/10.1007/s13555-024-01266-1>

McKee, S., Xenakis, J., Makin, H., Marshall, C., Winette, R., Aggarwal, R., Knight, S. Development of the Cutaneous Dermatomyositis Investigator Global Assessment (CDM-IGA): A De Novo IGA of Cutaneous Manifestations of Dermatomyositis. *Dermatol and Therapy* (2024). <https://doi.org/10.1007/s13555-024-01220-1>

Makin et al. (2024). Saliency versus ranking: exploring the utility of tasks used in qualitative research to identify concepts that are most useful to patients. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Wratten et al. (2024). Qualitative literature review to explore the patient experience of rheumatoid arthritis and unmet treatment needs to inform clinical trial patient-reported and digital endpoints. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Zeidler et al. (2024). Validation of a scoring algorithm for the clinician-reported outcome tool 'prurigo activity and severity (PAS)' based on clinical studies of dupilumab in adults with Prurigo Nodularis. *Journal of the European Academy of Dermatology and Venereology*

Zeidler et al. (2023). Validation of a Scoring Algorithm for the Clinician-Reported Outcome "Prurigo Activity and Severity (PAS)" Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis. Accepted by ISPOR EU, November 12-15 2023, Copenhagen Denmark

Williams-Hall R, Trennery C, Sully K, Wratten S, Francis A, Chandler D, Flynn J, Turner M, Marks DJB, Sackeyfio A, Bracher M, Walker A, Walker-Nthenda L, Arbuckle R, & Keeley T. A qualitative study to explore the symptoms and impacts of Crohn's disease and to develop the Crohn's Disease Diary. *Quality of Life Research* 2023

Wratten et al. (2023). "I'll Live Less, You'll Live Better, Let's Make It Count": A Qualitative Exploration of Drivers & Barriers for Sacrificing Remaining Life Expectancy to Restore Relatives to Full Health in Time Trade Off Exercises. Poster at ISPOR EU, November 12-15 2023, Copenhagen, Denmark

Wratten S, Abetz-Webb L, Arenson E, Griffiths P, Bowman S, Hueber W, Ndife B, Kuessner D, Goswami P. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). *RMD Open* 2023, 9(1)

Maruszczuk K, McMullan C, Aiyegbusi OL, Keeley T, Wilson R, Collis P, Bottomley C, Calvert MJ. Paving the way for patient centricity in real-world evidence (RWE): Qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation. *Heliyon*. 2023;14:e20157

Rozjabek HM, Macey J, Marshall C, McKee S, Popova V, Jamieson C. Qualitative study to assess the patient perspective on anhedonia symptoms and impacts in major depressive disorder. Poster presented at Psych Congress, 6–10 September 2023, Nashville, TN, US

McKee S, Marshall C, Kitchen H, Aldhouse N, Carmichael C. Incorporating the patient perspective into clinician reported outcome (ClinRO) content validation and meaningful withinpatient change thresholds. Presented at ISOQOL Annual Conference, 18-21 October 2023, Calgary, Canada

Maruszczuk K, McMullan C, Aiyegbusi OL, Keeley T, Wilson R, Collis P, Bottomley C, Calvert MJ. Considerations for Wider Implementation of Patient-Reported Outcomes in Real-World Evidence Generation: Stakeholder Interviews. ISOQOL 2023 Annual Conference. Calgary, Canada

Kim BS, Stander S, Rhoten S, Wratten S, O'Malley JT, Bansal A, Mshid J, Brookes E, Thomas R, Bahloul D. Validation of the Skin pain numeric rating scale (NRS) in prurigo nodularis (PN) based on clinical studies of dupilumab in adults with PN. Presented at American Academy of Dermatology Association 2023 Annual Meeting, March 17-23 2023, New Orleans

Edge H, Collins E, Kitchen H, Biller OM, Chan EKH, Aldhouse NVJ. A qualitative interview study into the experiences of fatigue and depression in chronic hepatitis B. Accepted by ISPOR EU, November 12-15 2023, Copenhagen Denmark.

Ford DM, Budworth L, Lawton R, Teale EA, O'Connor DB. In-hospital stress and patient outcomes: A systematic review and meta-analysis. *Plos one*. 2023 Mar 9;18(3):e0282789

Carmichael C, Shinde S, Al-Jassar G, Kanu C, Poon JL, Marshall C, Ezendu K, Makin H, Dang X, Weaver TE. Understanding the Lived Experience of Obstructive Sleep Apnea and Obesity: A Qualitative Study to Support Patient-Focused Measurement Strategies. Presented at Sleep 2023, Indianapolis

Carmichael C, Collins E, Marshall C, Macey J. Qualitative Content Analysis for Concept Elicitation (CACE) in Clinical Outcome Assessment Development. Presented at ISPOR EU, November 12-15 2023, Copenhagen Denmark

Al-zubeidi T, Makin H, Minor C, Smolkina E, Hakimi-Hawken N. Concept elicitation interviews to refine a conceptual model of the patient experience of amyotrophic lateral sclerosis (ALS). Presented at ISPOR EU, November 12-15 2023, Copenhagen Denmark.

Amini F, Alsawady M, Borecka O, Bottomley C. Caregiver burden in growth hormone deficiency: A targeted review. ISOQOL 2023 Annual Conference. Calgary, Canada.

Batchelor L, Wratten S, Praet A, Krol M. Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population. Poster at ISPOR EU, November 12-15 2023, Copenhagen Denmark

Bajpai SK, Jouravskaya I, Collins E, Burns DS, Kanu C, Mojdami D, Carmichael C. Participant Perceptions of the Single-Use Injection Pen Device in the SURMOUNT-4 Study. Presented at Obesity Week, 14-17 October 2023, Dallas, US

Bottomley C, Llewellyn S, Borecka O, Richardson L, Biggane AM. Approaches and challenges in developing caregiver vignettes in rare, progressive, and fatal childhood conditions: learnings from vignette development in Duchenne Muscular Dystrophy (DMD). ISOQOL 2023 Annual Conference. Calgary, Canada

Brookes E, Lucats L, Krol M, Wratten S, Afroz N, Arnould B. Patient experiences in hidradenitis suppurativa: Conceptual model and review of patient-reported outcome measures. Accepted at EADV, October 11-14 2023, Berlin Germany.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NV, Macey J, Mesinkovska N, Ko JM, King BA. Using qualitative methods to establish the clinically meaningful threshold for treatment success for the Severity of Alopecia Tool (SALT) score. Quality of Life Research Special Section: Methodologies for Meaningful Change 2022

Llewellyn S, Bottomley CJ, Borecka O. When is a patient a patient? Diagnosis validation in patientcentered research. National PROMS Annual Conference, June 2022, virtual

Aldhouse NVJ, Kitchen H, Al-zubeidi T, Thursfield M, Winnette R, See Tai S, Zhu L, Garnier N, Baker CL. Development of a conceptual model of the patient experience of focal segmental glomerulosclerosis (FSGS) - a qualitative literature review. Presented at ISPOR US 2022, May 2022

Aldhouse NVJ, Kitchen H, Al-zubeidi T, Thursfield M, Winnette R, See Tai S, Zhu L, Garnier N, Baker CL. Development of a conceptual model of the patient experience of immunoglobulin A nephropathy (IgAN) - a qualitative literature review. Presented at ISPOR US 2022, May 2022

Macey J, Farrar M, O'Donoghue C, Knight SL, Carmichael C, Marshall C, Yonan C, Imel EA, Salam M, Mulhern B. The Adjunctive Therapy Preferences of Adults With Classic Congenital Adrenal Hyperplasia: A Discrete Choice Experiment. Presented at ISPOR US 2022, May 2022

Manahan R, Macey J, Farrar M, O'Donoghue C, Knight SL, Carmichael C, Marshall C, Yonan C, Imel EA, Salam M, Mulhern B. Patient Preference Research: Preferred Adjunctive Medication Attributes of Adult Patients with Classic Congenital Adrenal Hyperplasia. Presented at ENDO 2022, June 2022.

Williams-Hall R, Tinsley K, Kruger E, Johnson C, Bowden A, Cimms T, Gater A. Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders. *Therapeutic Advances in Endocrinology and Metabolism*. 2022 Jan; 13

Macey J, Kitchen H, Aldhouse NV, Edson-Heredia E, Burge R, Prakash A, King BA, Mesinkovska N. A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome (PRO) measures. *British Journal of Dermatology*. 2022 May;186(5):849-60

Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley CJ, Ni Dhochartaigh S, Tran I, Leslie I, Schmid P. Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. *Health and Quality of Life Outcomes*. 2022; 18: 353

Jones MV, Smith N, Burns D, Braithwaite E, Turner M, McCann A, Walker L, Emmerson P, Webster L, Jones M, 2022. A systematic review of resilient performance in defence and security settings. *PLoS ONE*, 17(10) p.e0273015.

Guan Y, Nguyen AM, Wratten S, Randhawa S, Weaver J, Arbelaez F, Fauconnier A, Panter C. The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient reported outcome (PRO) for endometriosis related pain. *Journal of Patient-Reported Outcomes* 2022, 6(5)

Burns D, Brown Hajdukova E, Knight S, Macey J, Kitchen H. Developing a distress protocol for emotional distress in adults during remote COA interviews: A rapid review. Poster presented at ISOQOL 29th Annual Conference, October 2022.

Gorsh B, Perera S, Eliason L, Molinari A, Hanna M, Landi S, Nair S, Chakraborty A, Carmichael C, Patel P. Literature Review of Patient-Reported Outcome Measures in Multiple Myeloma: Trends and Considerations for Future Clinical Trials. Presented at ISPOR EU 2022, Vienna

Vincent SA, Borecka O, Llewellyn S, Bottomley CJ. 'How Easily Could You Obtain Proof of Diagnosis for Your Medical Condition?' Feedback From Individuals With Chronic Medical Conditions on a Digital Diagnosis Validation Feature. ISPOR 2022 Annual European Congress, November 2022, Vienna, Austria

McKee S, Marshall C, Makin H, Knight S, Winnette R, Xenakis J. Approaches to accurately assess cutaneous manifestation severity in dermatomyositis patients. Presented at EADV 2022 Conference, 7-10 September 2022, Milan, Italy and Virtual

Poon JL, Marshall C, Johnson C, Pegram H, Hunter H, Kan H, Ahmad, NN. A qualitative study to examine meaningful change in physical function associated with weight-loss. *Quality of Life Research Special Section: Methodologies for Meaningful Change*. July 2022.

Kitchen H, Gandhi K, Carmichael C, Wyrwich KW, Lukic T, Al-Zubeidi T, Marshall C, Pegram H, King S, King B. A Qualitative Study to Develop and Evaluate the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) Measures. *Dermatology and Therapy*. 2022 Aug; 12(8), 1907-24.

Griffiths N, Wratten S, Flynn J, Bookman AAM, Ndife B, Hueber W, & Goswami P. Content Validity of Sjögren's Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy Fatigue in Patients with Sjögren's. *Rheumatology & Therapy* 2022, 9(6), 1559-1574. Doi: 10.1007/s40744-022-00487-0

Kitchen, H., Wyrwich, K. W., Carmichael, C., Deal, L. S., Lukic, T., Al-Zubeidi, T., Marshall, C., Pegram, H., Hamzavi, I. H., & King, B. (2022). Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI). *Dermatol Ther (Heidelb)*, 12(7), 1623-1637. <https://doi.org/10.1007/s13555-022-00752-8>

Cooper C, Wratten S, Williams-Hall R, Bookman AAM, Ndife B, Hueber W, & Goswami P. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's. *Rheumatology & Therapy* 2022, 9(6), 1499-1515. DOI: 10.1007/s40744-022-00487-0

Aldhouse NVJ, Kitchen H, Al-zubeidi T, McKee S, Oriol Mathieu V, El Khoury A.C., Chan E.K.H. A qualitative interview study to explore perceptions of a prophylactic vaccine for human immunodeficiency virus (HIV). Presented at AIDS 2022 conference, 29th July-2 nd August 2022, Montreal, Canada

Ofari A, Ravindra H, Hall K, Bottomley C, Quinn C, Larkin M, Heinrich M. Contextualizing qualitative analysis with quantitative data on the symptoms and side effects associated with melanoma treatment in the real world – the value of patient registries. ISOQOL 28th Annual Conference, October 2021, virtual.

Holmes S, Podger L, Bottomley CJ, Rzepa E, Bailey K, Chandler F. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and healthrelated quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom. *Hematology*. 2021; 26: 465-472.

Elsner S, Salek s, Finlay AY, Hagemeyer A, Bottomley CJ, Katalinic A, Waldmann A. Validation of the German version of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on the partner or family member. *Health Qual Life Outcomes*. 2021; 19: 106.

Wratten S, Finbow C, Hatton S, Jones A, Wells J, Young A. Everyone Should Be Invited to the PROM: Diversifying Patient Reported Outcome Measures for LGBTQ+ Inclusion. Presented at ISPOR Europe, Dec 2021.

Iff J, McKee S, Johnson C, McNeill C, Sehinovych I, Muntoni F, Hencricson E, Kitchen H. Conceptual Models of the Patient Experience of Duchenne Muscular Dystrophy Constructed from a Qualitative Interview Study with Caregivers. Presented at ISPOR Europe, Dec 2021.

Goswami P, Wratten S, Griffiths N, Cooper C, Flynn J, Williams-Hall R, Abetz-Webb L, Hueber W, Ndife B. Sjogren's Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) for Assessments of Symptoms in Sjogren's Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change. Poster presentation at American College of Rheumatology (ACR) Convergence (Virtual) 3 - 9 November 2021.

Aldhouse NVJ, Kitchen H, Johnson C, Marshall C, Pegram H, Pease S, Collins, S., Baker CL, Katherine K, Crews C, & Wyrwich KW. (2021). Key Measurement Concepts and Appropriate Clinical Outcome Assessments in Pediatric Achondroplasia Clinical Trials. Poster presented at Virtual ACMG Annual Clinical Genetics Meeting. April 13-16.

Iff J, J. C., McKee S, Sehinovych I, McNeill C, Tesi-Rocha C, Kitchen H. A Qualitative Patient Experience Study of Eteplirsen Treatment for Duchenne Muscular Dystrophy. Presented at ISPOR Europe, Dec 2021.

Stepien K, Fatoye F, Yeowell G, Burns D. Burden of treatment and quality of life in patients with urea cycle disorders. Symposium held at the International Congress of Inborn Errors of Metabolism (Sydney/Hybrid), 21-24 Nov 2021.

Ning Q, Xie Q, Gish R G, Cohen C, Wang S, Cornberg M, Yatsushashi H, Brunetto M, Toumi M, Slagle A F, van Bömmel F, Marshall C, Macey J, Pegram H, Beumont-Mauviel M, Sbarigia U, Kitchen H, Villasis Keever A, Chan E K H, Wallace J. (2021) Content development of a new self-stigma patient-reported outcome instrument for chronic hepatitis B: A qualitative study in China. Asian Pacific Association for the Study of the Liver (APASL). Bangkok, Thailand, February 4–6; 2021.

Kitchen, H., Seitz, C., Trigg, A., Aldhouse, N., Willgoss, T., Schmitz, H., Gater, A., Gerlinger, C., & Haberland, C. (2021). Patients' and clinicians' perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). *Health Qual Life Outcomes*, 19(1), 7. <https://doi.org/10.1186/s12955-020-01579-7>

Kitchen H, G. K., Johnson C, Wyrwich KW, Lukic T, Al-Zubeidi T, Marshall C, Pegram H, King S, King B. A Qualitative Study to Explore the Content Validity of the Vitiligo Patient Priority Outcome (ViPPO) Measures. Presented at Vitiligo International Symposium, Dec 4, 2021.

Macey, J., Kitchen, H., Aldhouse, N. V. J., Burge, R. T., Edson-Heredia, E., McCollam, J. S., Isaka, Y., & Torisu-Itakura, H. (2021). Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan. *Dermatol Ther (Heidelb)*. <https://doi.org/10.1007/s13555-020-00477-6>

Marshall C, P. H., Macey J, Cohen C, Toumi M, Wallace J, Slagle AF, Markus M, Wang S, Yatsushashi H, Ning Q, Brunetto M, Gish RG, Xie Q, van Bömmel F, Beumont-Mauviel M, Villasis Keever A, Sbarigia U, Chan EKH, and Kitchen H. Participant Global Impression of Change (PGI-C) for Self-Stigma in People with Chronic Hepatitis B: A Cognitive Debriefing Study. Poster presented at Global Hepatitis Summit 2021, June 18-20.

Toumi M, W. J., Cohen C, Kitchen H, Macey J, Pegram H, Slagle AF, Wang S, Gish RG, Ning Q, Yatsushashi H, Cornberg M, Brunetto M, van Bömmel F, Xie Q, Sbarigia U, Beumont-Mauviel M, Villasis Keever A, Chan EKH, and Marshall C. Development and content validation of a new self-stigma patient reported outcome instrument for chronic hepatitis B: A concept elicitation and cognitive debriefing study in Asia, Europe, and United States. Poster presented at Global Hepatitis Summit 2021, June 18-20.

Goswami P, Wratten S, Cooper C, Flynn J, Griffiths N, Williams-Hall R, Abetz-Webb L, Bowman S, Hueber W, Ndife B. Patient and Physician Perspectives on EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) and EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): 13 Qualitative Interview Study. Poster presented at American College of Rheumatology (ACR) Convergence (Virtual) 3 - 9 November 2021.

Goswami P, Wratten S, Abetz-Webb L, Arenson E, Greenwood M, Williams-Hall R, Griffiths P, Bowman S, Huever W, Ndife B, Kuessner D. Exploring Alternative Responder Definitions for EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) for Use in Sjogren's Clinical Trials. Poster presentation at American College of Rheumatology (ACR) Convergence (Virtual) 3 - 9 November 2021.

Goswami P, Wratten S, Flynn J, Cooper C, Griffiths N, Williams-Hall R, Abetz-Webb L, Ndife B. Patient and Physician Response Scale Preferences for Clinical Outcome Assessments in Sjogren's: A Qualitative Comparison of Visual Analogue Scale, Numerical Rating Scale, and Likert Scale Response Options. Poster presentation at ISPOR EU (Virtual) 30 November - 3 December 2021.

Guan Y, Arbelaez F, Nguyen A, Wratten S, Panter C, Arbuckle R, Weaver J. Challenges and solutions in the implementation of clinical trial exit interviews to bring greater patient centricity to future trial procedures. Poster presentation at ISOQOL (Virtual) 12 – 28 October 2021.

Bentley S, Findley A, Chiva-Razavi S, Naujoks C, Patalano F, Johnson C, Arbuckle R, Wolffsohn JS. Understanding the visual function symptoms and associated functional impacts of phakic presbyopia. *Journal of Patient-Reported Outcomes*. 2021;5(1):1-15.

Bentley S, Findley A, Chiva-Razavi S, Naujoks C, Patalano F, Johnson C, Arbuckle R, Wolffsohn JS. Evaluation of the content validity of patient-reported outcome (PRO) instruments developed for use with individuals with phakic presbyopia, including the Near Activity Visual Questionnairepresbyopia (NAVQ-P) and the near vision correction independence (NVCI) instrument. *Journal of Patient-Reported Outcomes*. 2021 Dec;5(1):1-6.

Kitchen H, Wyrwich KW, Johnson C, Deal LS, Lukic T, Gandhi K, Al-Zubeidi T, Marshall C, Pegram H, Hamzavi IH, King B. P1250 Meaningful changes in what matters to patients with vitiligo. Presented at European Academy of Dermatology and Venereology Congress, Sept 29-Oct 2 2021.

Makin H, Chisholm A, Fallon V, Goodwin L. Use of motivational interviewing in behavioural interventions among adults with obesity: A systematic review and meta analysis. *Clinical obesity*. 2021 May 6:e12457.

Chatzidamianos G, Burns D, Andriopoulou P, Archer D, du Feu M. The challenges and facilitators to successful translation and adaptation of written self-report psychological measures into sign languages: A systematic review. *Psychological Assessment*. 2021 Sep 16.

Yeowell G, Burns DS, Fatoye F. The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study. *Journal of Patient-Reported Outcomes*. 2021 Dec;5(1):1-3.

Toumi M, Wallace J, Cohen C, Kitchen H, Macey J, Pegram H, Slagle AF, Wang S, Gish RG, Ning Q, Yatsuhashi H, Cornberg M, Brunetto M, van Bömmel F, Xie Q, Sbarigia U, Beumont-Mauviel M, Villasis Kever A, Chan EKH, and Marshall C. Development and content validation of a new selfstigma patient reported outcome instrument for chronic hepatitis B: A concept elicitation and cognitive debriefing study in Asia, Europe, and United States. Poster presented at Global Hepatitis Summit 2021, June 18-20.

Schroeder M, Hall K, Eliasson L, Bracey S, Gunsoy NB, Macey J, Jones PW, Ismaila AS. Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*. 2021;8(1):19.

Humphreys G, Evans R, Makin H, Cooke R, Jones A. Identification of Behavior Change Techniques From Successful Web-Based Interventions Targeting Alcohol Consumption, Binge Eating, and Gambling: Systematic Review. *Journal of medical Internet research*. 2021;23(2):e22694.

Ning Q, Xie Q, Gish RG, Cohen C, Wang S, Cornberg M, Yatsuhashi H, Brunetto M, Toumi M, Slagle AF, Bömmel F, Marshall C, Macey J, Pegram HC, Beumont-Mauviel M, Sbarigia U, Kitchen H, Villasis Keever A, Chan EKH, Lee D, Wallace J. Content development of a new self-stigma patient-reported outcome instrument for chronic hepatitis B: A qualitative study in China. Poster presented at Asian Pacific Association for the Study of the Liver (APASL), February 4–6, 2021.

Burns D, Dagnall N, Holt M. Assessing the impact of the COVID-19 pandemic on student wellbeing at universities in the United Kingdom: A conceptual analysis. In *Frontiers in Education* 2020 Oct 14 (Vol. 5, p. 204). Frontiers.

Yeowell G, Burns D, Fatoye F, Gebrye T, Wright A, Mwacalimba K, Odeyemi I. Indicators of HealthRelated Quality of Life in Cats With Degenerative Joint Disease: Systematic Review and Proposal of a Conceptual Framework. *Front Vet Sci*. 2021 Nov 18;8:582148.

Makin H, Chisholm A, Fallon V, Goodwin L. Use of motivational interviewing to support weightrelated behaviour change in obesity care: a systematic review and meta-analysis. Poster presented at the International Congress of Behavioral Medicine (Conference postponed due to COVID-19)

Gish R, Cornberg M, Wallace J, Ning Q, Brunetto M, Cohen C, Wang S, Toumi M, Slagle AF, Xie Q, van Bömmel F, Marshall C, Macey J, Pegram HC, Beumont-Mauviel M, Sylvester SV, Sbarigia U, Habuka N, Takahashi Y, Kitchen H, and Chan EKH, Yatsuhashi, H. Content Development of a Patient-Reported Outcome Instrument to Measure Self-Stigma in Chronic Hepatitis B: A Qualitative Concept Elicitation and Cognitive Debriefing Study in the United States. 56th Annual Meeting of the Japan Society of Hepatology (JSH) May 21-22, 2020. (The poster session was canceled due to COVID-19, but the abstract was published in the conference proceeding.)

Knight S, Johnson C, Dulani J, Marshall C, Aldhouse N, Macey J, Pegram H, Hunter M, AlZubeidi T, McKee S, Kitchen H. Social media listening in PRO development: Can online conversations contribute to our conceptualization of a disease area? Accepted for oral presentation at ISOQOL 27th Annual Conference (Virtual), 2020.

Crawford R, Sully K, Conroy R, Johnson C, Doward L, Bell T, Welch V, Peloquin F, Gater A. PatientCentered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers. *The Patient*, 2020 Feb;13(1):83-102

Randhawa S, Wratten S, Abetz-Webb L, Arbuckle R, Scott J. The Psychological, Emotional, Physical, Social, and Economic Burden of Caring for a Child with Respiratory Syncytial Virus (RSV): A Qualitative and Quantitative Literature Review. Poster presentation at ISPOR Europe (Virtual), 16-19 November 2020.

Llewellyn S, Hall K, Camidge L, Bottomley CJ, Nixon A, Larkin M. Patient-centricity in action: using patient feedback to adapt the PRO-CTCAE instrument in a real-world study. ISOQOL 27th Annual Conference, October 2020, virtual.

Hall K, Llewellyn S, Bottomley CJ, Larkin M. Melanoma patient registries: a targeted review and comparison of datasets. ISOQOL 27th Annual Conference, October 2020, virtual.

Kretz S, Spinage C, Bottomley CJ. Challenges with using paper format legacy Patient-Reported Outcome Measures in digital real-world evidence studies for apps. ISOQOL 27th Annual Conference, October 2020, virtual.

Richards A, Bottomley CJ. Gamification- the future of real-world patient-reported studies? Analysis of the ethical and legal challenges of applying gamification in observational studies using smartphone apps: a review of the UK and France. ISOQOL 27th Annual Conference, October 2020, virtual.

Ofari A, Llewellyn S, Bottomley C, Kousoulakou H. What role does caregiver burden play in health technology assessment bodies' appraisals of highly specialized technologies? ISPOR 2020 Annual European Congress, November 2020, virtual.

Guan Y, Nguyen A, Fauconnier A, Weaver J, Panter C, Wratten S, Randhawa S, Arbuckle R, Giudice L, Arbelaez F. Uncovering Hidden Symptoms in Women with Endometriosis. Poster presentation at The Society of Endometriosis and Uterine Disorders (SEUD) 6th Annual Congress (Virtual), 2-6 November 2020.

Guan Y, Panter C, Wratten S, Randhawa S, Arbuckle R, Fauconnier A, Giudice L, Arbelaez F, Weaver, J, Nguyen, A. The Endometriosis Daily Diary: Modifying an Existing PRO for EndometriosisRelated Pain. Oral presentation at ISOQOL 27th Annual Conference (Virtual), 19-23 October 2020.

Pegram HC, Knight S, Marshall C, Macey J, Aldhouse NVJ, Johnson C, Al-Zubeidi T, Hunter M, Kitchen H. “How do I ask that?” Recommendations for using patient appropriate language during qualitative interviews to develop fit-for-purpose clinical outcome assessments (COAs). Poster presented at ISOQOL 27th Annual Conference (Virtual), 2020.

Johnson C, Kitchen H, Marshall C, Macey J, Aldhouse NVJ, Al-Zubeidi T, Pegram HC, Hunter M, Knight S. Ethical considerations when accessing, analyzing, and reporting social media data. Poster presented at ISOQOL 27th Annual Conference (Virtual), 2020.

Pegram HC, Johnson C, Hunter M, Knight S, Macey J, Aldhouse NVJ, Al-Zubeidi T, Kitchen H, Marshall C. Recommendations to enable patients to discuss physical functioning concepts in a way they can understand during qualitative interviews. Poster presented at ISOQOL 27th Annual Conference (Virtual), 2020.

Wolffsohn JS, Leteneux-Pantais C, Chiva-Razavi S, Bentley S, Johnson C, Findley A, Tolley C, Arbuckle R, Kommineni J, Tyagi N. Social Media Listening to Understand the Lived Experience of Presbyopia: Systematic Search and Content Analysis Study. *Journal of Medical Internet Research*. 2020 Sep;22(9)

Bentley S, Johnson C, Exall E, Brohan E, Lawrance R, Bennett B, Bargo D, Zanotti G, Staehler M, Stewart GD. Improving patient-clinician communication following nephrectomy in Renal Cell Carcinoma: Development, content validation and pilot testing of a Conversation Aid Tool. *Patient Education and Counseling*. 2020 June;104(1):99-108

Poon JL, Marshall C, Johnson C, Pegram H, Hunter M, Kan H, Ahmad N. A Qualitative Study in Obesity to Explore Clinically Meaningful Change on Patient-Reported Outcome (PRO) Measures. Presented at the American Diabetes Association’s Annual Scientific Sessions, June 2020, Virtual Conference.

Kitchen H, Farrar M, Al-zubeidi T, Pegram H, Hunter T, Naegeli AN, Delbecque L, Jairath V. Patient perspective on disease burden, remission definition and symptoms associated with treatmentseeking: A qualitative study in adult and adolescent patients with Crohn’s disease. Accepted for publication, 21st April 2020, *Crohns & Colitis* 360

Schulz A, Jain M, Butt T, Ballinger R, Eliasson L, Macey J, Peasgood T, Olaye A, Terzakis-Snyder I, Dyck I, West A. The Challenges of Living with and Caring for a Child or Children Affected by Neuronal Ceroid Lipofuscinosis Type 2 Disease: In-Depth Family Surveys in the United Kingdom and Germany. *Journal of Inborn Errors of Metabolism and Screening*. 2020 May 18.

Johnson C, Pegram H, Marshall C. Assessing physical functioning and activities of daily living (ADLs)- can the same clinical outcome assessments (COAs) be used to measure both concepts? Accepted at ISPOR US 2020.

Bernarde J, Yang HK, Barnes G, Bottomley CJ, Tang B. Development of a novel conceptual model to describe the patient reported impact of living with non-small cell lung cancer. ISPOR 2020 Annual Congress, May 2020, virtual.

Poon JL, Marshall C, Johnson C, Pegram H, Hunter M, Kan H, Ahmad N. Development of a Conceptual Model to Present the Impacts of Obesity on Physical Functioning. Accepted at the Endocrine Society's Annual Meeting 2020 (Conference cancelled due to COVID-19).

Hong YD, Keeley T, Shen Q, Alfonso Cristancho R, Kitchen H, Marshall C, Salerno V, Hennig M. Patient-Reported Outcomes in the German Health Technology Assessment Process: Requirements for the Minimally Important Difference. Accepted for presentation at DGGO, March 23-24, 2020 (conference cancelled due to COVID)

Hong YD, Hennig M, Shen Q, Alfonso Cristancho R, Kitchen H, Marshall C, Salerno V, Keeley T. Assessing the Impact Of Patient-Reported Outcomes (PROs) In Health-Technology Assessment (HTA). Presented at ISPOR US 2020 (virtual).

Wyrwich KW, Kitchen H, Knight S, Aldhouse NV, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of the Scalp Hair Assessment Patient Reported Outcome™(PRO) Measure for Alopecia Areata. *British Journal of Dermatology*. 2020 Mar 12.

Holmes SJ, Podger L, Bernarde J, Bottomley CJ, Chandler F. Survivorship in acquired thrombotic thrombocytopenic purpura (aTTP) – impacts on quality of life (QoL) and cognitive functioning in patients from the UK. 25th Congress of the European Hematology Association (EHA). June 2020, virtual.

Ziemssen, T., Piani-Meier, D., Bennett, B., Johnson, C., Tinsley, K., Trigg, A., Hach, T., Dahlke, F., Tomic, D., Tolley, C., & Freedman, M. S. (2020). A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. *J Med Internet Res*, 22(2), e16932. <https://doi.org/10.2196/16932>

Hunter T, Naegeli A, Delbecque L, Al-zubeidi T, Pegram H, Kitchen H. P117 Content Validity of the Subcutaneous Administration Assessment Questionnaire (SQAAQ) in Adult and Adolescent Patients with Moderate to Severe Crohn's Disease. *Inflammatory Bowel Diseases*. 2020. 26(Supplement_1);S42-43.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NV, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. The Alopecia Areata Investigator's Global Assessment (AA IGATTM) Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials. *British Journal of Dermatology*. 2020 Jan 23.

Aldhouse, N. V. J., Kitchen, H., Knight, S., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., King, B. A., & Wyrwich, K. W. (2020). "You lose your hair, what's the big deal?" I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata. *J Patient Rep Outcomes*, 4(1), 76. <https://doi.org/10.1186/s41687-020-00240-7>

Knight S, Johnson C, Dulani J, Marshall C, Aldhouse N, Macey J, Pegram H, Hunter M, Al-Zubeidi T, McKee S, & Kitchen H. Social media listening in PRO development: Can online conversations contribute to our conceptualization of a disease area? Accepted for oral presentation at ISOQOL 27th Annual Conference (Virtual), 8 June; 2020.

Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. *Am J Clin Dermatol*, 21(5), 725-732. <https://doi.org/10.1007/s40257-020-00545-9>

Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020b). Development of the Scalp Hair Assessment PRO measure for alopecia areata. *Br J Dermatol*, 183(6), 1065-1072. <https://doi.org/10.1111/bjd.19024>

Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020a). The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *Br J Dermatol*, 183(4), 702-709. <https://doi.org/10.1111/bjd.18883>

Kitchen H, Farrar M, Al-zubeidi T, Pegram H, Hunter T, AN, N., Delbecque L, & Jairath V. (2020). Patient's perspective on disease burden, remission definition and symptoms associated with treatment-seeking: A qualitative study in adult and adolescent patients with Crohn's disease. *Crohns & Colitis* 360, 2(2), otaa033.

Macey J, Marshall C, Aldhouse NV, Al-Zubeidi T, Pegram HC, Staccuneddu M, Knight S, & Kitchen H. Recommendations for conducting cognitive interviews remotely to develop clinical outcome assessments. Presented at ISPOR EU 2019, 2-6 November 2019, Copenhagen, Denmark.

Ballinger R, Macey J, Lloyd A, Chen K. Impact on carers of adult patients receiving parenteral support for short bowel syndrome-associated intestinal failure. Presented at ISPOR EU 2019, 2-6 November 2019, Copenhagen, Denmark.

Ballinger R, Macey J, Lloyd A, Chen K. Impact on carers of paediatric patients receiving parenteral support for short bowel syndrome-associated intestinal failure. Presented at ISPOR EU 2019, 2-6 November 2019, Copenhagen, Denmark.

Marshall C, Macey J, Aldhouse NV, Al-Zubeidi T, Pegram HC, Staccuneddu M, Knight S, Kitchen H. Patient-centered methods: Considerations for exploring sensitive topics during patient interviews to develop clinical outcome assessment (COA) measures. Presented at ISOQOL 26th Annual Conference, 20-23 October 2019, San Diego, CA, USA.

Al-zubeidi, T, Kitchen H, Pegram H, Aldhouse NVJ, Delbecque L, Hunter T, Farrar M, Naegeli AN. Application of patient-centric methods in clinical outcomes assessment research; patient feedback from a qualitative interview study in Crohn's disease. *QUALITY OF LIFE RESEARCH* 28, S138-S138. Presented at ISOQOL 26th Annual Conference, 20-23 October 2019, San Diego, CA, USA.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King BA. A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata. Presented at European Academy of Dermatology and Venerology 28th Congress, 9-13 October 2019, Madrid, Spain.

Johnson C, Kilgariff S, Exall E, Brohan E, Lawrance R. Using statistical study design concepts in the evaluation of patient education tools. Presented at PROMS Research Conference 2019, 13th June 2019.

de Freitas, H.M., Ito, T., Hadi, M., Al-Jassar, G., Henry-Szatkowski, M., Nafees, B., Lloyd, A.J. Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries. 2019. *Advances in Therapy*: 1-15.

Eriksson, J., Amonkar, M., Al-Jassar, G., Lambert, J., Malmenäs, M., Chase, M., Sun, L., Kollmar, L., Vichnin, M. Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer. 2019. *Journal of Clinical Medicine*, 8(4): 558

Marshall C, Aldhouse NV, Macey J, Al-Zubeidi T, Pegram HC, Kitchen H. Patient-Centered Methods: Considerations for Qualitative Research to Support Content Validity When Developing Clinical Outcome Assessment (COA) Measures Appropriate for Adolescent Patients (Aged 12-17 Years Old). *Value in Health*. 2019 May 1;22: S289.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King BA. Development and Content Validation of a Clinically Meaningful Patient-Reported Outcome (PRO) for Scalp Hair Assessment. Presented at 24th World Congress of Dermatology, Milan 2019, 24 April

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King BA. Development and Content Validation of Clinically Meaningful Clinician-Reported Outcome (ClinRO) Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata. Presented at 11th World Congress for Hair Research, 24-27 April 2019, Barcelona Spain.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King BA. The Alopecia Areata Global Assessment (AA-IGA) Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials. Presented at American Academy of Dermatology (AAD) Annual Meeting, 1-5 March 2019, Washington, DC, US.

Elstein D, Klemen M, Panter C, Bonner N, Johnson C and Zimran A. Gaucher disease (GD)-specific patient-reported outcome (PRO) measures for clinical monitoring and for clinical trials. Presented at WORLD Symposium 2019, 4-8 February 2019.

Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes F, Dutronc Y, Mesinkovska N, Ko J, King BA. The Role of Patients in the Development of the Alopecia Areata Investigator Global Assessment (AA-IGA™), a Clinician-Reported Measure Evaluating Clinically Meaningful Success in Clinical Trials. Presented at National Alopecia Areata Foundation (NAAF) Research Summit, 4-5 December 2018, New York, US.

Johnson CD, Williamson N, Janssen-van Solingen, G, Arbuckle R, Johnson C, Simpson S, Staab D, Dominguez-Munoz JE, Levy P, Connett G, Lerch MM. Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI). *Pancreatology*. 2019 Jan 1;19(1):182-90.

Macey J, Knight SL, Tosh J, Lee J. PRM184-Analysis of Utility Values Used in NICE Appraisals of Highly Specialised Technologies. *Value in Health*. 2018 Oct 1;21: S387-8.

Ballinger R, Macey J, Lloyd A, Brazier J, Ablett J, Burden S, Lal S. Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. *Clinical therapeutics*. 2018 Nov 1;40(11):1878-93.

Svedsater H, Doll HA, Macey J, Miles G, Bradshaw L, Vanya M. Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences. *Advances in therapy*. 2018 Sep 1;35(9):1378-99.

Hartry A, Aldhouse NVJ, Al-zubeidi T, Sanon M, Stefanacci R, Knight S. (2018) The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, 10: 498-508.

Kitchen H, Al-Zubeidi T, Mathers L, Paik J, DeLozier A. A qualitative study to explore the content validity of patient reported outcome measures in a systemic lupus erythematosus population. *Value in Health* 21, S257.

Kitchen H, Haberland C, Trigg A, Aldhouse NVJ, Willgoss T, Schmitz H, Gater A, Gerlinger C, Seitz C. A qualitative study exploring patients' and clinicians' perspectives on item importance, scoring preferences, and clinically meaningful differences for two patient-reported outcomes (PRO) measures for endometriosis: Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Accepted for oral presentation at ISOQOL 25th Annual Conference, Dublin, October 2018

Kitchen H, Chan EK, Aldhouse NVJ, Pegram HC, Scott JA (2018). Cognitive debriefing interviews to explore the content validity of the chronic liver disease questionnaire (CLDQ) and EQ-5D-5L in patients with chronic Hepatitis B. *Value in Health*, 21, S156.

Aldhouse NVJ, Kitchen H (2018) Assessing Quality in Qualitative Research to Understand Disease Burden; What Tools are Available? *Value in Health* 21, S230

Cimms T, Ali QA, Kilgariff S, Johnson C, Arbuckle R, Malkus B and Haller C. Qualitative Research to Characterize Patients with Galactosialidosis. Presented at WORLD Symposium 2018, 5-8 February 2018.

Rylands AJ, Boxell E, Bottomley CJ. Key Considerations For The Collection Of Patient Reported Outcome Data In Real World Studies. ISPOR 21st Annual European Congress, November 2018, Barcelona, Spain.

Adlard N, Watson J, Bottomley CJ, Kroes M. A three month interim analysis of Fingolimod Treatment Adherence for relapsing remitting multiple sclerosis in the UK: the Patient Reported Outcomes with Fingolimod in local Experience (PROFILE) study. ISPOR 21st Annual European Congress, November 2018, Barcelona, Spain.

Adlard N, Brisbane F, Watson J, Bottomley CJ, Kroes M. A three month interim analysis of quality of life in patients with relapsing remitting multiple sclerosis in the UK: the Patient Reported Outcomes with Fingolimod in Local Experience (PROFILE) study. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 2018, Berlin, Germany.

Rylands AJ, Boxell E, Bottomley CJ. Key considerations for the collection of patient centred data in the real world. UK PROMS conference, June 2018, Birmingham, UK.

Keetley M, Pulfer A, Bottomley CJ. How is Real World Data Currently Used by Industry Professionals? ISPOR 23rd Annual International Meeting, May 2018, Baltimore, USA.

Gaffney K, Dunkley L, Goodson N, Kerrigan S, Marshall D, Savanovic-Abel O, Sengupta R, Mackay C, Tsoumani E, McCann E, Bottomley CJ, Futter T, Hickey J. A multi-centre retrospective study to describe the real world effectiveness of golimumab for treating ankylosing spondylitis (AS) in UK clinical practice. British Society of Rheumatology Annual Congress, May 2018, Liverpool, UK.

Bottomley CJ, Lloyd A, Bennett G, Adlard N. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. *Journal of Medical Economics*. 2017;20:863-870.

Brégigeon-Ronot S, Cheret A, Cabié A, Prazuck T, Volny-Anne A, Ali S, Bottomley CJ, Finkielsztejn L, Philippe C, Parienti JJ. Evaluating patient preference and satisfaction for human immunodeficiency virus therapy in France. *Patient Preference and Adherence*. 2017; 11:1159-1169.

Degboe A, S. S., Halling K, Trigg A, Al-Zubeidi T, Aldhouse A. Qualitative interviews to understand the patient experience of head and neck squamous cell cancer and explore the content validity of patient reported outcome measures. Poster A120 presented at ISPOR 22nd Annual International Meeting. Boston, MA USA; May 20-24; 2017.

Degboe A, Kitchen H, Aldhouse NVJ, Trigg A, Herman JM, Narang A, Hodgkin M, Johnson C, Halling K. A qualitative interview study to explore the patient experience of locally advanced or metastatic pancreatic cancer and the content of patient-reported outcome measures. Presented at ISPOR 20th Annual European Congress, 4–8 November 2017, Glasgow, Scotland.

Trigg A, Kitchen H, Chan E, Willgoss T, Sears J, Aldhouse NVJ, Pierson RF, Scott J. Patients' Experiences Living with Chronic Hepatitis B Infection: A Multinational Qualitative Study. Presented at ISPOR 20th Annual European Congress, 4–8 November 2017, Glasgow, Scotland.

Lee J, Kitchen H, Fletcher-Louis M. The Role of Patient-Reported Outcomes and Patient Engagement in Health Technology Assessments and Reimbursement Decision Making in 10 Countries. Presented at ISPOR 20th Annual European Congress, 4–8 November 2017, Glasgow, Scotland.

Moshkovich O, Benjamin K, Macey J, Doll HA, Hill CL, Hall AK. Development of the OIQOL-A: A Health-Related Quality of Life Measure for Adults with Osteogenesis Imperfecta. Poster presented at ISPOR 20th Annual European Conference: 2017 November 4-8; Glasgow, UK.

Verrill M, Schmid P, Retzler J, Smith SB, Bottomley CJ, Dando S, Tran I, Leslie I, Wardley A. Work Productivity in HER2 Positive Breast Cancer: A Comparison of Patients Across Stages of Early and Metastatic Disease. ISPOR 20th Annual European Congress, November 2017, Glasgow, UK.

Gaffney K, Dunkley L, Goodson N, Kerrigan S, Marshall D, Savanovic-Abel O, Sengupta R, Mackay C, Tsoumani E, McCann E, Futter T, Hickey J, Bottomley CJ. A Multi-Centre Retrospective Study To Describe The Impact on Healthcare Resource Use And Real World Effectiveness of Golimumab In Ankylosing Spondylitis (AS) In UK Clinical Practice. ISPOR 20th Annual European Congress, November 2017, Glasgow, UK.

Rylands AJ, Owen G, Toms J, Heggs N, Bottomley CJ. The Development And Use Of A Preliminary Conceptual Model Of Inflammatory Bowel Disease (IBD) To Facilitate Patient Reported Outcome (PRO) Instrument Selection For A UK Real-World Evidence Study. ISPOR 20th Annual European Congress, November 2017, Glasgow, UK.

Baker CL, Bruno M, Grant L, Johnson C, Bennett B, Brohan E, Emir B. Content Validity of a Willingness to Quit Tool for Use with Current Smokers in Clinical Practice. *Advances in therapy*. 2017 Oct 1;34(10):2295-306.

Theodore-Oklotka C., Arbuckle R, Marshall C and Spencer H. (2017) Qualitative research to explore the pediatric patient experience with X-Linked Hypophosphataemia (XLH) and to evaluate the content validity of PROMIS® item banks, FPS-R® and POSNA-PODCI for use as clinical trial endpoints. Presented at 10th International Meeting of Pediatric Endocrinology (IMPE) conference, 14-17 Sept 2017, Washington D.C., USA.

Shingler S, Aldhouse N, Al-zubeidi T, Trigg A, Kitchen H. The Development and Use of Conceptual Models. Presented at Advances in Patient Reported Outcomes Research Conference, 8 June 2017, St Anne's College, Oxford. Abstract published in *Health and Quality of Life Outcomes*, 2017 15(Sup 1): 185.

Thalange N, Aldhouse NVJ, Kitchen H, Howard D, Tutkunkardas, D, Håkan-Bloch, J. (2017) Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK. *Diabetes Therapy*, 1-14

Trigg A, Andersson FL, Aldhouse N, Bliwise DL, Kitchen H. (2017) Patients' lived experiences of nocturia: A qualitative study of the evening, the night, and the next day. *The Patient-Patient Centered Outcomes Research*, 1-8, doi: 10.1007/s40271-017-0241-021

Gelhorn, H., Anand, S., Parvizi, J., Morrison, T., Yu, H., Pokrzywinski, R., Al-Jassar, G., Chen, A. Qualitative Interviews to Identify the Burden of Illness, the Impact and the Costs Associated with Post-Operative Infections. 2017. *Journal of Comparative Effectiveness Research*, (4):357-367

Kitchen H, Aldhouse N, Trigg A, Palencia R, Mitchell S. (2017) A review of patient reported outcome measures to assess female infertility related quality of life. *Health and Quality of Life Outcomes*, 15(86), doi: 10.1186/s12955-017-0666-0

Ballinger RS, Llewellyn S, Macey J, Eliasson E, Butt T, Jain M, Olaye A, West A. Validating Outcome Assessments For HTA In CLN2, An Ultra-Rare Disease. Presentation: HTAi 2017 Annual Meeting (VS26); 2017 June 17-21; Rome, Italy.

von Maltzahn R, Arbuckle R, Marshall C, et al. (2017) Conducting qualitative 'exit' interviews following clinical trials or observational studies: A valuable method for understanding the patient experience, informing measurement strategy and aiding interpretation of patient-reported outcomes. Presented as a workshop at ISPOR 22nd Annual International Meeting, 20-24 May 2017, in Boston, MA, USA.

Degboe A, Shingler SL, Halling K, Trigg A, Al-Zubeidi T, Aldhouse NV, Kitchen H (2017) Qualitative interviews to understand the patient experience of squamous cell carcinoma of the head and neck and explore the content of patient reported outcome measures. *Value in Health* 20(5), A120.

Trigg A, Kitchen H, Willgoss T, Ho KF, Pierson R, Scott J. Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) Fatigue Severity Scale (FSS), Center for Epidemiologic Studies Depression Scale (CES-D), and the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-Free Simeprevir-Containing Regimen (2017). In submission.

Kerr C, Bottomley C, Shingler S, Giangregorio L, de Freitas H, Patel C, Randell S, & Gold D. (2017). The importance of physical function to people with osteoporosis. *Osteoporosis International*, 28(5), 1597-1607, doi: 10.1007/s00198-017-3911-9.

Svedsater H, Roberts J, Patel C, Macey J, Hilton E, Bradshaw L. Life Impact and Treatment Preferences of Individuals with Asthma and Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups. *Advances in Therapy*. 2017 May; 1-6.

Humphrey L, Willgoss T, Trigg A, Meysner S, Kane M, Dickinson S, Kitchen H. A comparison of three methods to generate a conceptual understanding of a disease based on the patients' perspective. *Journal of Patient-Reported Outcomes* (2017) 1:9.

Tran I, Campbell V, Lawson C, Bottomley CJ, Al-Jassar G, Glen F, Lloyd AJ. Health state utility and quality of life in first remission from diffuse large b-cell lymphoma (DLBCL). ISPOR 21st Annual International Meeting, May 2016, Washington, USA.

Wyrwich, K.W., Gries, K.S., Al-Jassar, G., Bacci, E.D., Chen, Y., Jain, R., Konkol, L., Merilainen, M.J. and Weng, H.H. Assessing the Content Validity of the Investigator-Rated ADHD Rating Scale Version IV Instrument Inattention Subscale for Use in Adults With Phenylketonuria. 2016. *Journal of Inborn Errors of Metabolism and Screening*, (4): 1–7

Ballinger RS, Macey J, Lloyd AJ, Brazier JE. Utilities Associated with The Number of Days on Parenteral Support in The Treatment of Short Bowel Syndrome. *Value in Health*. 2016 Nov;19(7):A513.

Gelhorn, H., Anand, S., Parvizi, J., Morrison, T., Yu, H., Pokrzywinski, R., Al-Jassar, G., Chen, A. The Burden of Illness, Impact and Costs Associated with Post - Operative Infections: The Patient Perspective. 2016. Poster presentation at 25th European Bone & Joint Infection Society (EBJIS).

Bottomley CJ, Padania S, Lloyd AJ, Bennett G, Green C, Adlard N. UK Patient Preference For Characteristics Of DMTs In MS. Association of British Neurologists, May 2016. Brighton, UK.

Gater A, Kitchen H, Heron L, Pollard C, Håkan-Bloch J, Højbjørre L, Strandberg-Larsen M. (2015). Development of a conceptual model evaluating the humanistic and economic burden of Crohn's disease: implications for patient-reported outcomes measurement and economic evaluation. *Expert Review of Pharmacoeconomics & Outcomes Research*, (0), 1-14.

Shingler S, Fordham B, Evans M, Schroeder M, Thompson G, Dewilde S, Lloyd AJ. (2015) Utilities for treatment-related adverse events in type 2 diabetes. *J Med Eco*, 18(1):45-55

Tse J, Shingler S, Nixon A. The emerging role of patient-reported outcomes (PROs) in FDA hematology and oncology product labels. Presented at ISPOR 20th Annual International Meeting, Philadelphia, USA, 2015

Shingler SL, Grant C, McKendrick J. The contribution of informal caregiver burden to HTA in hematological cancers in France, Germany and the US. Presented at ISPOR 18th Annual European Congress, Milan, Italy: 7-11 November 2015.

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. (2015). Content development and refinement for a new Patient reported outcome measure for Psoriasis Treatment (PROMPT). *Value in Health*, 18(3), A184-A185.

Trigg A, Kitchen H, Willgoss TG, Meysner S, Humphrey L. (2015) Reviewing Clinical Outcome Assessment Usage In Clinical Trials: Introducing The Cola Methodology. *Value in Health*, 18(3), A35

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. (2015). Rasch analysis of a new Patient reported outcome measure for Psoriasis Treatment (PROMPT). *Value in Health*, 2015,18(3)

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. (2015). Patient reported outcome measures in psoriasis: the good, the bad and the missing! *British Journal of Dermatology*, 172(5), 1210-1221.

Nguyen AM, Humphrey L, Kitchen H, Rehman T, Norquist JM. (2015). A qualitative study to develop a patient-reported outcome for dysmenorrhea. *Quality of Life Research*, 24(1), 181-191.

Padania S, Bottomley CJ, Adlard N, Watson J, Lloyd AJ. Using A Mixed Methods Approach to Develop A Discrete Choice Experiment In Multiple Sclerosis. ISPOR 18th Annual European Congress, November 2015. Milan, Italy

Quinn C, Shingler SL, Hirji I, Davis C. Mapping health state utility values from EORTC data collected from a clinical trial population with relapsed/refractory multiple myeloma. Presented at ISPOR 18th Annual European Congress, Milan, Italy: 7-11 November 2015

Willgoss TG, Trigg A, Meysner S, Kitchen H, Humphrey L, Blankenburg M. (2015). Understanding the Suitability of Cystic Fibrosis-Specific Clinical Outcome Assessments For Clinical Trials and to Support Medical Product Labeling. *Value in Health*, 18(3), A286.

Nixon A, Kerr C, Doll H, Naegeli AN, Shingler SL, Breheny K, Burge R, Gold DT, Silverman S. Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function. *Osteoporos Int.* 2014 Jun;25(6):1775-84

Gazzard B, Ali S, Muhlbacher A, Ghafouri N, Maggiolo F, Golics CJ, Nozza S, Fuster M, Antela A, Parienti J, Dang N, Ronot Bregigeon S, Benzie A, Murray, M. Patient preferences for characteristics of antiretroviral therapies: results from 5 European countries. *HIV Drug Therapy*, November 2014. Glasgow, UK

Golics CJ, Basra MKA, Finlay AY, Salek MS. The development and validation of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on partner or family member. *Quality of Life Research.* 2014; 23: 317-26

Ballinger R, Friedemann C, Golics CJ, Lloyd A, Doyle S. Impact of non-consented switch and subsequent switch in asthma medication: qualitative study of patient perspective in the UK. ISPOR 17th Annual European Congress, November 2014. Amsterdam, The Netherlands

Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerg L, Hansen BB. (2014). Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. *Health Qual Life Outcomes*, 12, 116.

Murray M, Dang N, Gallop C, Golics CJ, de Freitas H, Lloyd AJ. Evaluating Patient Preferences For HIV Therapy: Results From A Discrete Choice Experiment In The UK And Germany. ISPOR 19th Annual International Meeting. May 2014, Montreal, Canada

Shingler SL, Bennett BM, Cramer JA, Towse A, Twelves C, Lloyd AJ. Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. *Curr Med Res Opin*. 2014 Nov;30(11):2329-41

Simmonds, R., Glogowska, M., McLachlan, S., Al-Jassar, G., Johnson, R., Cramer, H., Sanders, T., Lasserson, D., Kadam, U., Purdy, S. 'HoldFAST': A Multicentre, Longitudinal, Ethnographic Study on Heart Failure and Unplanned Hospital Admissions. 2014. SAPC Presentation, Edinburgh

Simmonds, R., Glogowska, M., McLachlan, S., Al-Jassar, G., Johnson, R., Cramer, H., Sanders, T., Lasserson, D., Kadam, U., Purdy, S. Exploring the Issue of Psychological Distress in Patients with Symptomatic Heart Failure. Could this be a Risk Factor for Unplanned Hospital Admissions? 2014. Paper presented at the Primary Care Mental Health Conference, and poster presented at 'The Comorbidity Conference'

Shingler S, Swinburn P, Ali S, Perard R, Lloyd A. A Discrete Choice Experiment to Determine Patient Preferences for Injection Devices in Multiple Sclerosis. *Journal of Medical Economics*, 2013 Aug; 16(8):1036-42. doi: 10.3111/13696998.2013.811079

Bowtell, N., Al-Jassar, G., Gray, C., Kelsey, K., Verner, J. Universal Provision but Practical Challenges in Access: The UK Case. 2013. *Economia & Lavarò*, (3): 91-101

Golics CJ, Basra MKA, Finlay AY, Salek MS. The impact of patients' chronic disease on family quality of life: an experience from 26 specialties. *International Journal of General Medicine*. 2013; 6: 787- 98

Golics CJ, Basra MKA, Salek MS, Finlay AY. The validation of the final version of the Family Reported Outcome Measure (FROM-16). ISOQOL 20th Annual Conference, October 2013. Miami, USA

Golics CJ, Basra MKA, Salek MS, Finlay AY. The impact of disease on family members: a critical aspect of medical care *J R Soc Med* 2013; 106(10): 399-407

Kitchen H, Bekker Hansen B, Abetz A, Hojbjerg L, Strandberg-Larsen M. Patient-Reported Outcome Measures for Rheumatoid Arthritis: Minimal Important Differences Review. *Arthritis & Rheumatism*, 2013, vol 65, S965

Shingler SL, Swinburn P, Lloyd A, Diaz J, Isbell R, Manson S, Benson C. Elicitation of health state utilities in soft tissue sarcoma. *Quality of Life Research*. 2013; 22(7):1697-706

Shingler SL, Howard C; Johnston K; Lloyd AJ. Patient preferences for therapies in epilepsy. Presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA May, 2013

Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. *Journal of Medical Economics*. 2013; 16(6):777-83. doi: 10.3111/13696998.2013.800822

Swinburn P, Shingler S, Ong SH, Lecomte P, Lloyd A. Assessing the health related quality of life of patients hospitalised for acute heart failure. *British Journal of Cardiology*, 2013; 20:72–6. doi: 10.5837/bjc.2013.013

Swinburn P, Shingler S, Won-Seog K, et al. Health state utilities for relapsed/refractory (REL/REF) Hodgkin's Lymphoma (HL) and systemic anaplastic large-cell lymphoma (sALCL): Asian Pacific county data. Presented at the 5th ISPOR Asia Pacific Congress, Taipei, Taiwan; 2-4 September 2012

Swinburn P, Shingler S, Ali S, Perard R, Lloyd A. Preferences of multiple sclerosis patients for attributes of self-injection devices. Presented at ISPOR 17th Annual International meeting, Washington DC, USA; 2-6 June 2012

Swinburn P, Shingler S, Ong SH, Lloyd A. Quality of life in acute heart failure. Presented at World Congress of Cardiology, Dubai, United Arab Emirates; 18-21 April 2012

Golics CJ, Basra MKA, Salek MS, Finlay AY. The Development and Content Validation of a Novel Generic Family Quality of Life Instrument: the Family Reported Outcome Measure. ISOQOL 19th Annual Conference, October 2012. Budapest, Hungary

Golics CJ, Basra MKA, Salek MS, Finlay AY. The Family Reported Outcome Measure: initial validation of a generic QoL measure for family members of patients with chronic medical conditions. 42nd Annual Meeting of the European Society for Dermatological Research, September 2012. Venice, Italy

Kitchen H, Marshall C . (2012) An interactive overview of using Computer-Assisted Qualitative Data Analysis Software (CAQDAS) in health outcomes research. Presented at ISOQOL 19th Annual Conference, 24-27 Oct 2012, in Budapest, Hungary

Kitchen H, Rofail D, Heron L, Sacco P. Cognitive Impairment Associated with Schizophrenia: a Review of the Humanistic Burden. *Adv Ther* (2012) 29(2):148-162

Kitchen H, Rofail D, Caron M, Emery MP. (2011). Oncology patient-reported claims: maximising the chance for success. *ecancermedicalsecience*, 5

Golics CJ, Basra MKA, Salek MS, Finlay AY. Diseases profoundly affect the quality of life of family members of patients. 41st Annual Meeting of the European Society for Dermatological Research, September 2011. Barcelona, Spain.

Golics CJ, Basra MKA, Salek MS, Finlay AY. A qualitative inquiry into the effects of disease on the family and the partner- "The Greater Patient". ISOQOL 18th Annual Conference, October 2011. Denver, USA.

Golics CJ, Basra MKA, Salek MS, Finlay AY. Keynote speech: The Impact of Disease on the Lives of Family Members. 14th Congress of the European Society for Dermatology and Psychiatry, March 2011. Zaragoza, Spain

Salek MS, Basra MKA, Tanweer Z, Fenech D, Howe A, Mehbouba T, Golics C, Finlay AY. Refinement and validation of Teenager's Quality of Life Questionnaire (T-QoL). ISOQOL 18th Annual Conference, October 2011. Denver, Colorado

Shingler S, Robertson L, Boghossian S, Stewart M. Compression stockings for the initial treatment of varicose veins in patients without venous ulceration. *Cochrane Database Syst Rev*. 2011 Nov 9;(11):CD008819. doi: 10.1002/14651858.CD008819.pub2. Review. (updated 2021)

Golics CJ, Basra MKA, Finlay AY, Salek MS. Adolescents with Skin Disease Have Specific Quality of Life Issues. *Dermatology*. 2009; 218: 357-366

Golics CJ, Olasuga A, Howard P. An audit of adherence of web-based clostridium difficile guidelines. *Infection*, November 2009. Birmingham, UK

Psychiatry

Voelker J, K. E., Nash A, Neslusan C, Sheeran J, Wilkinson ST. (2020). What are the attributes that psychiatrists consider in the decision to discharge adults with major depressive disorder who have been hospitalized with active suicidal ideation with intent? Poster presented at Virtual ISPOR May 18-20, 2020. *Value in Health*, 23(S210).

Rajagopalan, K., Trueman, D., Crowe, L., Squirrell, D., & Loebel, A. (2016). Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. *Pharmacoeconomics*, 34(7), 709-721. <https://doi.org/10.1007/s40273-016-0405-0>

Lockhart, I. A., Mitchell, S. A., & Kelly, S. (2009). Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. *Dement Geriatr Cogn Disord*, 28(5), 389-403. <https://doi.org/10.1159/000255578>

Lockhart I, M. S., Kelly S. (2009) A systematic review of the real-world study evidence comparing the safety and tolerability of donepezil, rivastigmine, galantamine for the treatment of mild to moderate Alzheimer's disease. Presented at ISPOR 12th Annual European conference; Paris, France; October 24-27; 2009.

Dakin HA, S. M. (2003). Cost-effectiveness of clozapine to prevent suicide in schizophrenia: interim results. *J Psychopharmacol*. 2003;17(3 (suppl)):A54 (abstract E48).

Duggan, A., Warner, J., Knapp, M., & Kerwin, R. (2003). Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. *Br J Psychiatry*, 182, 505–508.

Duggan AK, M. J. (2001). Should Clozaril be used early or late in treatment pathways – a health economic perspective. 'The earlier use of Clozaril: a discussion'.

Respiratory

Schechter, M. S., Trueman, D., Farquharson, R., Higuchi, K., & Daines, C. L. (2015). Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis. An economic evaluation. *Ann Am Thorac Soc*, 12(7), 1030-1038. <https://doi.org/10.1513/AnnalsATS.201312-453OC>

Bentley, A., Filipovic, I., Gooch, K., & Büsch, K. (2013). A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. *Health Econ Rev*, 3(1), 18. <https://doi.org/10.1186/2191-1991-3-18>

Schlechter MS, T. D., Farquharson R, Higuchi K, Daines C. (2012). An economic evaluation of aztreonam lysine for inhalation and tobramycin for inhalation, in an intermittent aerosolised antibiotic regime, among cystic fibrosis patients with chronic pulmonary pseudomonas aeruginosa infection. Presented at American Thoracic Society International Conference; p.A6733. San Francisco; May 18-23; 2012.

Haughney J, G. M., Dakin HA, Ballabio M, Caputo G. (2007). Cost-effectiveness of erdosteine in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). *Thorax*. 2007;62(Suppl III):A47.

Niziol, C. (2004). Respiratory care in community settings. *Nurs Stand*, 19(4), 41-45. <https://doi.org/10.7748/ns2004.10.19.4.41.c3721>

Price, D., Thomas, M., Mitchell, G., Niziol, C., & Featherstone, R. (2003). Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. *Respiratory Medicine*, 97(1), 12-19. <https://doi.org/DOI 10.1053/rmed.2002.1426>

Duerden M, W. T., Mitchell G, Niziol C. (2003). Rates of transition up the British Asthma Guidelines steps of care in UK general practice. Presented at 22nd European Academy of Allergy and Clinical Immunology Congress; Paris, France; 2003.

Thomas, M., Price, D., Mitchell, G., & Niziol, C. (2002). Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: A prescribing claims study of 1,701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI. 12th European Respiratory Society Annual Congress, Stockholm.

Price, D., Mitchell, G., & Niziol, C. (2001). Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: A prescribing claims study of 7,412 patients using a CFC-MDI or a breath-actuated device. 13th European Respiratory Society Annual Congress, Berlin.

Rheumatology

Perez-Ruiz F, K. P., Karra G, Burton H, Jansen T. (2018). A summary of clinical evidence for commonly used uricosurics for gout in Europe. Poster SAT0360. *Annals of the Rheumatic Diseases*. 2018.

Orme M, F. I., Mitchell S, Spurden D, Bird A. (2011). Systematic review and network meta-analysis of combination therapy for methotrexate-experienced, rheumatoid arthritis patients: Analysis of American College of Rheumatology criteria scores 20, 50 and 70 (ACR 20/50/70). Presented at ACR/ARHP Annual Scientific Meeting; Chicago, IL; 4-9 November; 2011.

Surgery

Patel, A. S., Bergman, A., Moore, B. W., & Haglund, U. (2013). The economic burden of complications occurring in major surgical procedures: a systematic review. *Appl Health Econ Health Policy*, 11(6), 577-592. <https://doi.org/10.1007/s40258-013-0060-y>

Taylor, R. S., Ryan, J., O'Donnell, R., Eldabe, S., Kumar, K., & North, R. B. (2010). The cost-effectiveness of spinal cord stimulation in the treatment of failed back surgery syndrome. *Clin J Pain*, 26(6), 463-469. <https://doi.org/10.1097/AJP.0b013e3181daccec>

Howard S. (2004). Abacus International Survey. A survey measuring the impact of NICE guidance 24: The use of debriding agents and specialist wound care clinics for difficult to heal surgical wounds.

Urology

Liu, F. X., Treharne, C., Culleton, B., Crowe, L., & Arici, M. (2014). The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis. *BMC Nephrol*, 15, 161. <https://doi.org/10.1186/1471-2369-15-161>

Liu FX, T. C., Arici M, Lees L, Davis I, Sloand J. (2012). Peritoneal dialysis and in-centre haemodialysis: a cost- effectiveness analysis. Poster presented at American Society of Nephrology Kidney Week. October, 2012.

Cardoza L, T. A., Grishenko M, Sidhu M. (2008). A cost utility analysis of solifenacin 5 mg and solifenacin 10 mg versus tolterodine ER in the pharmacological treatment of patients with OAB in the UK NHS. Presented at ISPOR 11th Annual European conference; Athens, Greece; November 8-11; 2008.

Kalsi, V., Popat, R. B., Apostolidis, A., Kavia, R., Odeyemi, I. A., Dakin, H. A., Warner, J., Elneil, S., Fowler, C. J., & Dasgupta, P. (2006). Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. *Eur Urol*, 49(3), 519-527. <https://doi.org/10.1016/j.eururo.2005.11.006>

Odeyemi, I. A., Dakin, H. A., O'Donnell, R. A., Warner, J., Jacobs, A., & Dasgupta, P. (2006). Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. *Int J Clin Pract*, 60(8), 949-958. <https://doi.org/10.1111/j.1742-1241.2006.01057.x>

Stratton, R. J., Bircher, G., Fouque, D., Stenvinkel, P., de Mutsert, R., Engfer, M., & Elia, M. (2005). Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kidney Dis*, 46(3), 387-405. <https://doi.org/10.1053/j.ajkd.2005.04.036>

Haycox A, D. A. (1996). Optimising the future development of dialysis services in the UK. *Br J Med Econ*. 1996;10:15–35.

Krupa BS, D. A., Haycox A. (1996). Costing renal service provision – the Shrewsbury Renal Revenue Model. *Br J Med Econ*. 1996;10:15–26.

Health economics

Bektur C LNM, Cornell M, Hide J, Xin Q, Howells R, Chang-Douglass S. (2024). Health economic evaluations incorporating broader perspectives: a targeted literature review. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Xin Q HS, Wang S, Massey R, Nair S, Chang-Douglass S. (2024). AI-assisted review of NICE guidance for highly specialized technologies: economic modelling of ultra-rare conditions. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Blandy O LP, Folorunso R, Myren KJ, Chevrou-Severac H, Thomas S. (2024). Acceptability of RWE by HTA Bodies Across Europe to Support Clinical Benefit Assessments of Rare Disease Therapies. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Tremblay, G., Howard, D., Tsong, W., Patel, V., & De Rosendo, J. (2018). Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective. *Epilepsy Behav*, 86, 108-115. <https://doi.org/10.1016/j.yebeh.2018.06.002>

Dakin, H., Sherman, M., Fung, S., Fidler, C., & Bentley, A. (2011). Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. *Pharmacoeconomics*, 29(12), 1075-1091. <https://doi.org/10.2165/11589260-000000000-00000>

Farquharson R, B. J., Kroes MA, Tumor I, Hendry L. (2011). Economic evidence in the context of HTA: the challenge of palliative care. Poster presented at HTAi 8th annual meeting; Rio de Janeiro, Brazil; 2011.

Hendry L, T. I., Farquharson R, Kroes MA. (2011). The challenges of estimating costs of palliative care: a systematic literature review. Poster presented at ISPOR 14th annual European congress; Madrid, Spain; November. 5-8; 2011.

Dakin, H., Bentley, A., & Dusheiko, G. (2010). Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. *Value Health*, 13(8), 922-933. <https://doi.org/10.1111/j.1524-4733.2010.00782.x>

Giglio N, G. A., Lees L, Micone P, Armoni J, Reygrobellet C. (2009). Public health and economic benefits of paediatric influenza vaccination programmes in Argentina. Presented at 6th World Congress of the World Society for Pediatric Infectious Disease; 2009.

Dakin H, B. T., Sherman M, Yoshida E, Gudaitis E, Canestraro B, et al. (2008) Cost-effectiveness of adding in adefovir following clinical or virologic resistance in chronic hepatitis B (CHB) patients. Presented at Canadian Digestive Disease Week (CDDW) and Fourth Annual CASL Winter meeting. Canada; 2008.

Dakin, H. A., Devlin, N. J., & Odeyemi, I. A. (2006). "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making. *Health Policy*, 77(3), 352-367. <https://doi.org/10.1016/j.healthpol.2005.08.008>

Devlin N, P. D., Dakin H. (2005). NICE decision making in the UK: new evidence on the influence of cost effectiveness, quality of evidence and uncertainty. Presented at 5th World Congress of the International Health Economics Association; Barcelona, Spain; July 10-13; 2005.

Duggan AK, D. H., Jackson DL. (2003). An updated Markov model evaluating donepezil: interim results. *Age Ageing*. 2003;32 (Suppl 2):ii43.

Riedler, G. F., Haycox, A. R., Duggan, A. K., & Dakin, H. A. (2003). Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. *Vox Sang*, 85(2), 88-95. <https://doi.org/10.1046/j.1423-0410.2003.00329.x>

Riedler, G. F., Haycox, A. R., Duggan, A. K., & Dakin, H. A. (2003c). Solvent-detergent-treated plasma may be cost-effective. *Vox Sang*, 84(4), 334; author reply 334-335. https://doi.org/10.1046/j.1423-0410.2003.00307_1.x

Haycox, A., Mitchell, G., Niziol, C., & Featherstone, R. (2002). Cost effectiveness of asthma treatment with a breath-actuated pressurised metered dose inhaler (BAI) – a prescribing claims study of 1,856 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. *J Med Econ*, 5, 65–77. <https://doi.org/10.3111/200505066077>

Other

Bonemei R NA, McCloskey C, Chidurala M, Daud S, Nair S. (2024). Clinical, economic and humanistic burden of SIDS/SUID in the USA and Europe. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain

Nas de Tourris et al. (2025) Thinking of zebras. Delivering innovative medicines to patients with rare diseases. Clarivate insights on rare disease drug development. Available at: <https://clarivate.com/life-sciences-healthcare/lp/thinking-of-zebras/2025>

Chivite M CA, Massey R, Ricci C. (2024). Cost analysis and environmental impact estimation of polypropylene iodine contrast media containers compared with glass containers: a UK hospital. Presented at ISPOR, 17th-20th November 2024, Barcelona, Spain.

Hashim S BG, Leatham O, Massey R. (2024). Will the Joint Clinical Assessment help address inequality in advanced therapy medicinal products access across Europe? Presented at HTAi in Seville, 15-19 June 2024.

Moore P, Danchenko N, Weidlich D, Tijerina AR. (2024). Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event. *PLoS One*. 2024;19(2):e0296340.

Clark-Wright, J., Hudson, P., McCloskey, C., & Carroll, S. (2020). Burden of Selected Infectious Diseases Covered by UK Childhood Vaccinations: Systematic Literature Review. *Future Microbiology*, 15(17), 1679-1688. <https://doi.org/10.2217/fmb-2020-0170>

Adam, J., Malone, R., Lloyd, S., Lee, J., Hendriks, C. J., & Ramaswami, U. (2019). Disease progression of alpha-mannosidosis and impact on patients and carers - A UK natural history survey. *Mol Genet Metab Rep*, 20, 100480. <https://doi.org/10.1016/j.ymqmr.2019.100480>

Lowen C, Lavallee C, Seelam P, Balakrishnan S, Henrikson A, Kesting B, & Torres KA. (2019). Real-World Evidence of Clinical Characteristics and Tolerance Outcomes Among Adult Post-Acute Care Patients Receiving Peptide-Based Diets in the US. *Clinical Nutrition*, 38.

Figlar H, A. M., Wray J, Hoskins N, Fletcher-Louis M, Casanova C. (2018). The growing importance of digital channels in formulary decision making in the US. Presented at ISPOR 21st Annual European Congress. Barcelona, Spain, November 10-14; 2018.

Finocchiaro, D., Rastelletti, I., De-Almeida, J., Lloyd, S., & Gupta, P. (2018). A Systematic Review of the Epidemiology of Alpha-Mannosidosis. *Value in Health*, 21, S249. <https://doi.org/10.1016/j.jval.2018.04.1684>

James F, T. J., Eccleston A, Eaton LH, Bennett E, Gupta J. (2018). Service impact modelling as a tool to support market access for health technology innovation. Presented at ISPOR 21st Annual European Congress. Barcelona, Spain, November 10-14; 2018.

Crown W, B. N., Thokala P, Morton A, Sir MY, Marshall DA. (2017). Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. *Value Health*. 2017;20(3):310-9.

Witkowski M, H. P., Batson S, Moore B, Mitchell S. (2017). Systematic review of healthcare use and needs of prisoners. *Health Services Research (HSR)* Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 293.D/2017/10.273/68. 2017

Batson, S., Greenall, G., & Hudson, P. (2016). Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis. *PLoS One*, 11(5), e0154870. <https://doi.org/10.1371/journal.pone.0154870>

Batson, S., Mitchell, S. A., & King, D. (2014). The Use and Acceptance of Novel Statistical Analyses To Support Technology Submissions To HTA Authorities. *Value in Health*, 17(7), A576-A577. <https://doi.org/10.1016/j.jval.2014.08.1943>

Trew, G. H., Brown, A. P., Gillard, S., Blackmore, S., Clewlow, C., O'Donohoe, P., & Wasiak, R. (2010). In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review. *Reprod Biol Endocrinol*, 8, 137. <https://doi.org/10.1186/1477-7827-8-137>

Niziol, C. (2005). Myth busting. *Nurs Stand*, 19(42), 70-71. <https://doi.org/10.7748/ns2005.06.19.42.70.c3899>

Howard S. Measuring the impact of NICE guidance across 28 disease areas. *Clinical Excellence* 2004. NICE conference publication. London: NICE; 2004. p. 110–8.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit clarivate.com.

Contact our experts today:

Richard Massey

Director | Value Communication

richard.massey@clarivate.com

+44 (0)20 7433 4000 (Europe)

+1 215 386 0100 (U.S.)

clarivate.com

© 2026 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.